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Preterm birth is a complex multifactorial process.  Despite the well-known role of the placenta in 
supporting the fetal development and maternal-fetal tolerance, the placental epigenetic modifications and 
preterm birth (PTB) remains poorly understood and under investigated.  Various maternal and 
environment factors can influence epigenetic programming during fetal development to affect the 
functioning and structures of organs, including the placenta, which can lead to adverse pregnancy 
outcomes, including PTB.  The understanding of the placental epigenetic alterations and maternal 
determinants associated with PTB are apparently indispensable for the development of actual diagnosis 
and methods of prevention and treatment of premature labor. The purpose of this dissertation is to identify 
epigenetic factors and predictor risks contributing to PTB.  To achieve this goal we conducted literature 
and systematic reviews to assess evidence from published, peer-reviewed epigenetic studies examining 
the association between human placenta epigenetic alterations and PTB.  In addition, we conducted an 
epidemiological study of predictor risks of PTB.  The review identified a few studies showing an 
association of epigenetic changes (DNA methylation, expression of miRNAs and mRNAs) with PTB.  
Although these studies have reported an association, their findings were not replicated across studies.  
Also, the results provide the evidence of methodological concerns and recommend the need for the use of 
standard quality reporting guidelines by journals, such as STROBE (STrengthening the Reporting of 
Observational Studies in Epidemiology) checklists to refine the quality under review.  The 
epidemiological assessment of various risk predictors of PTB was conducted using de-identified data 
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from the University of Hawaii Biorepository.  The findings show an association between PTB and 
different predictor risks.  
These results may help not only to understand the complexity of PTB, but also to standardize and 
to improve the quality of research related to placental epigenetic modifications and PTB.  This 
dissertation provides an understanding of predictor risks and genes of causal importance in PTB.  
Moreover, further research is required to replicate and address the limitations of previous placental 
epigenetic studies.  The finding of this epigenetic study lays the foundation of early stage screening and 
diagnostic of PTB, as well as suggesting therapeutic targets.  
  
iii 
 
 
 
TABLE OF CONTENTS 
ABSTRACT........................................................................................................................................................i 
TABLE OF 
CONTENTS......................................................................................................................................................iii 
LIST OF ABBREVIATIONS...............................................................................................................................iv  
ACKNOWLEDGEMENTS.................................................................................................................................vii 
GENERAL OVERVIEW………………………………………………………………......................................1 
CHAPTER 1: INTRODUCTION………………………………………………………………………………..3 
1.1. Introduction................................................................................................................................4 
1.2. Pregnancy……………………………………………………………………………………...4 
1.3. Human Placenta ........................................................................................................................5  
1.4. Role of placenta in preterm birth…………………………………………………………….7 
1.5. Epigenetics fundamental processes and mechanisms.............................................................9  
1.5.1. Epigenetics mechanisms………………………………………………………......10 
1.5.1. a. DNA methylation ..................................................................................................10  
1.5.1. b. Histone modifications............................................................................................10   
1.5.1. c. MicroRNA regulation……………………............................................................11  
1.5.1. d. Genomic imprinting ..............................................................................................12   
    1.5.2. Placenta and epigenetic modifications.....................................................................13   
1.5.2. a. Placenta- specific DNA methylation…………………………………………….13 
    1.5.2. b. Placenta- specific histone modifications ………………………………………….14 
1.5.2. c. Placenta- specific MicroRNA modifications ……………………………………14 
1.5.2. d. Placenta and genomic imprinting ……………………………………………….15 
1.6. Maternal factors, epigenetics, and PTB ……………………………………………………16 
1.7. Conclusion................................................................................................................................20 
1.8. References ……………………………………………………………………………………24   
CHAPTER 2: EPIGENETIC MODIFICATIONS OF HUMAN PLACENTA ASSOCIATED WITH  
PRETERM BIRTH: A SYSTEMATIC REVIEW……………………………………………………………...32 
 CHAPTER 3: DETERMINANTS OF PRETERM BIRTH IN A HAWAIIAN POPULATION:  
A CASE-CONTROL STUDY…………………………………………………………………………………55 
CHAPTER 4: SYNTHESIS & FUTURE DIRECTIONS………………………………………………………..76 
 
 
iv 
 
 
 
 
LIST OF ABBREVIATIONS 
AA                                                                                                                                      African American 
ACOG                                                                       American College of Obstetricians and Gynecologists 
ANOVA                                                                                                                          Analysis of variance  
BDNF                                                                                                      Brain Derived Neurotrophic Factor  
BMI                                                                                                                                     Body Mass Index  
BS                                                                                                                                   Bisulfite Sequencing  
DM                                                                                                                           Differential Methylation  
EMR                                                                                                                     Electronic Medical Record 
FLT-1                                                                                                              Fms-related Tyrosine kinase 1  
GA                                                                                                                                         Gestational Age  
HTN                                                                                       Arterial Hypertension or High Blood Pressure  
IPB                                                                                                                             Indicated Preterm Birth 
ISCU                                                                                               Iron-Sulfur Cluster Scaffold Homologue  
KDR                                                                                                             Kinase Insert Domain Receptor 
LMP                                                                                                                            Last Menstrual Period  
miRNA                                                                                                                     micro Ribonucleic Acid 
MMP                                                                                                                                 Metalloproteinase  
MSP                                                                                                                      Methylation-Specific PCR  
NA                                                                                                                                       Native American 
NGF                                                                                                                              Nerve Growth Factor  
NOS                                                                                                                         Newcastle Ottawa Scale  
NT                                                                                                                                            Normal Term  
OR                                                                                                                                               Odds Ratio 
v 
 
 
 
OXTR                                                                                                                                          Oxytocin 
Receptor PCR                                                                                                  Polymerase Chain Reaction  
PE                                                                                                                                           Preeclampsia  
PlGF                                                                                                                     Placental Growth Factor  
POL                                                                                                                    Premature Onset of Labor 
PPROM                                                                                    Preterm Premature Rupture of Membranes  
PROM                                                                                                     Premature Rupture of Membrane  
PT                                                                                                                                                    Preterm  
PTB                                                                                                                                        Preterm Birth  
PTL                                                                                                                                       Preterm Labor  
PTPE                                                                                                                      Preterm Pre-Eclampsia  
RRR                                                                                                                              Relative Risk Ratio  
RNA                                                                                                                                Ribonucleic Acid 
RT-PCR                                                                       Reverse Transcription Polymerase Chain Reaction  
RT-qPCR                            Real-Time Quantitative Reverse Transcription -Polymerase Chain Reaction  
SGA                                                                                                                   Small for Gestational Age  
SPB                                                                                                                   Spontaneous Preterm Birth 
STROBE                                   STrengthening the Reporting of OBservational studies in Epidemiology 
TL                                                                                                                                             Term Labor  
TNL                                                                                                                                     Term No Labor  
UCN                                                                                                                                             Urocortin  
   UHB                                                                                                    University of Hawaii Biorepository 
   U.S. DHHS                                                        United States Department of Health and Health Services             
VEGF                                                                                                  Vascular Endothelial Growth Factor 
 WIRB                                                                                                    Western Institutional Review Board 
 
vi 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To my Late Mother and Sister, 
You two Ladies are my Motivation 
 
 
 
  
vii 
 
 
 
ACKNOWLEDGEMENTS 
 
My sincere and special thank you to Dr. Debora Barnes-Josiah, my Advisor, for giving me gentle 
guidance and the resources necessary to conduct my research.  She has been generous with her time and 
attention during my study, which makes her a caring mentor.  She also helped me grow much as a 
researcher by allowing me to explore and develop my ideas.  I would not have completed this dissertation 
without her support.  
I am graciously thankful to the members of my dissertation committee, Dr. Lorena Baccaglini, 
Dr. David Klinkebiel, Dr. Fang Yu and Dr. Rosa Gofin, for providing me invaluable advice and 
inspiration by being knowledgeable and supportive.  Thank you for your time, encouragement, trust and 
recommendations that helped me to move forward and attain my research goals.  I would like to extend 
my appreciation to Dr. Baccaglini for her time commitment and her generosity in sharing her knowledge 
to help me being an expert in the systematic review study.  
I would like to thank Dr. Wael ElRayes and Teresa Hartman for their contribution in the 
systematic review process. Dr. ElRayes helped carried out the qualitative assessment of included article in 
the review. After the initial search, Teresa Hartman helped mapping the search and the bibliography.  I 
would like to express my gratitude to the University of Hawaii Biorepository Unit. Their help with de-
identified data has made it possible for me to carry out my research in a timely and efficient manner.  I 
extend my thanks to the University of Hawaii Biorepository (UHB) and Dr. Josh Astern my Co-PI, his 
help and generosity in compiling, sharing their data and helping me to get their IRB approval needed to 
perform part of my research.  The National Institute on Minority Health and Health Disparities and the 
National Institute General Medicine Sciences supported HUB project. Without these collaborations, it 
would have been undoubtedly difficult for me to make progress on my dissertation work. 
My Deepest thank you goes to Dr. Ayman El Mohandes, my Mentor, and friend.  I want to 
express my gratitude to all the past and present members of the Center for Reducing Health Disparities 
viii 
 
 
 
for their help and supports.  To Stephon McNeil, Antonia Correa to name but a few, thanks for hanging 
around with me and keeping me entertained.  It is my privilege to work with you all.  
I would like to acknowledge the support provided by the Department of Epidemiology and Health 
Promotion, Social and Behavioral Health through which I received my graduate training.  They have 
provided an inspiring academic environment for my professional growth and development. 
I would like to thank my family for their support and for always believing in me, especially my 
late mother Aminata Traore and sister Fanta Toure, my lovely son Sikon Drissa Toure.  I am deeply 
indebted to my wife Koudedia Sissoko and her family.  Without her love and support, it would not be 
possible for me to overcome all the challenges and difficulties. 
My deepest and straight gratefulness goes to Allah Almighty, who is my strength, source of 
wisdom, knowledge, and inspiration, and the reason for living.  I am forever indebted to Him for His love, 
grace, mercy, and blessings that make all things possible. 
 
1 
 
 
 
 
GENERAL OVERVIEW 
Preterm birth (PTB) is defined as babies born alive before thirty-seven completed weeks of 
gestation (World Health Organization, 2012).  Accepted sub-categories PTB, based on gestational age 
are: (1) extremely preterm (<28 weeks), (2) very preterm (28 to <32 weeks), and (3) moderate to late 
preterm (32 to <37 weeks) (Blencowe et al., 2012). PTB is a complicated process with three different 
obstetric phenotypes (Blencowe et al., 2012; Goldenberg et al., 2008).  First, delivery for maternal or fetal 
indications complications called indicated preterm birth (IPB), during which delivery is initiated either by 
medical induction or by a pre-labor cesarean section. Second, preterm rupture of membrane (PROM) and 
preterm premature rupture of membranes (PPROM), which can lead to birth either by vaginal or cesarean 
delivery. Last, spontaneous preterm birth (SPB) with intact membranes.  
Worldwide, the PTB rate is estimated to be around 11% (WHO, 2012).  The rate ranges from 5% 
in parts of Europe to 18% in some regions of Africa (WHO, 2012).  Nearly 15 million children are born 
preterm each year (Blencowe et al., 2012).  According to Blencowe et al. (2012), of these PTB, 5% 
occurred at less than 28 weeks, 10% took place at 28 to less than 32 weeks, and 84% at 32 to 36 weeks.  
Preterm birth is the leading cause of neonatal death (a death that occurs in the first 28 days of life) 
(Blencowe et al., 2012).  PTB is accountable for 27% of neonatal deaths worldwide and over one million 
deaths annually (Lawn et al., 2010; WHO, 2012).  Other adverse outcomes of preterm birth include 
neonatal morbidity and long-term sequelae such as neurodevelopmental deficits (e.g., visual disorders, 
cerebral palsy, impaired learning) (Pallotto et al., 2006).  Besides, PTB increases the risk of a spectrum of 
adult diseases including obesity and reduced developmental skills compared to term-born children 
(Mwaniki et al., 2012; Ozer, 2013; Pallotto et al., 2006).  Population-based data are useful for monitoring 
preterm birth trends, but more comprehensive data are needed to understand the problem of preterm birth 
and to assess known and suspected causal factors such as environmental factors, parental, and infant 
biomarkers. 
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Epigenetics is defined as the study of processes that produce changes in gene activity and 
expression without alteration of the DNA sequences (Bird, 2007).  Pregnancy is a period during which 
epigenetic modifications are active enlightening a continuous interaction between the internal and 
external environments required by the healthy development (Gheorghe et al., 2010 Kanherkar et al., 
2014).  Thus, embryonic and fetal growth processes depend on complex interactions between genetic, 
epigenetic and environmental factors (Maccani et al., 2013). Although our understanding of epigenetic 
variations in fetal and placental development are limited, there is growing evidence that they play 
significant roles in preterm birth.  Coan and colleagues defined imprinting as an epigenetic mechanism 
during which some genes are “silenced either in the egg or sperm and never expressed in the offspring” 
(see below1.5.2. d.). Imprinting occurs in the placenta and may have a demonstrable effect on the 
placental development and function (Coan et al., 2005).  
This dissertation aims to perform a systematic review of the literature on the main epigenetic 
modifications of human placental as it relates to the etiology of adverse pregnancy outcomes, especially 
preterm birth. Chapter 1, provides an outline of the current knowledge and understanding of the role of 
epigenetic regulation in fetal and placental development.  It is organized as follows: 1) introduce 
pregnancy, preterm birth, and the role of the placenta in PTB; 2) review basic epigenetic processes, 
mechanisms and their variations in the human placenta; and 3) discuss the link between environmental 
factors, epigenetics, and PTB.  Chapter 2, is a systematic review of available evidence from published, 
peer-reviewed studies examining the association between placental epigenetics abnormalities and preterm 
birth.  Lastly, Chapter 3, assesses determinants of PTB using de-identified data from the University of 
Hawaii Biorepository.  The results of this research provide further knowledge and understanding about 
the role of placental epigenetic modifications in PTB and various risk predictors of PTB in a Hawaiian 
population.  The findings lay the foundation of how this knowledge can be used to improve personalized 
medicine.  Thus, understanding of genes of etiological importance may aid in PTB diagnosis, prevention, 
and treatment strategies.   
 
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 1 
INTRODUCTION: THE ROLE OF EPIGENETIC REGULATION IN FETAL AND 
PLACENTAL DEVELOPMENT   
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1.1.  Introduction 
This chapter provides the current knowledge and understanding of the placenta and the role of 
epigenetic regulation in placental and fetal development.  This introduction provides first an overview of 
human pregnancy, placenta development, and the placenta’s role in preterm birth. Second, it provides a 
review of basic epigenetic processes, mechanisms, and their variations in the human placenta.  Last, it 
briefly discusses the link between environmental factors, which defines the parent’s lifestyles, 
epigenetics, and PTB. 
We conducted a comprehensive literature review of PubMed and Medline, with a limitation for 
articles written in the English and French languages.  Search terms used were placenta, preterm birth, and 
epigenetics.  Further, I manually searched the citation sections of all relevant studies or reviews for 
additional information. 
1.2. Pregnancy 
Pregnancy constitutes the period from conception to birth.  Typically, human pregnancies usually 
last 40 weeks, counting from the first day of the woman’s last menstrual period (LMP) to the estimated 
date of delivery (ACOG, 2013).  Pregnancy is considered as three trimesters, each lasting about three 
months (Jukic et al., 2013).  The LMP marks the start of the first trimester (conception to about twelve 
weeks), which is characterized by three major occurrences.  First, the fertilized egg develops into a 
blastocyst, implants into the uterus, and begins differentiating into placental and embryonic cells.  The 
second major factor is the process of organogenesis, during which primary cell layers of the embryo start 
to develop into organs.  The third key process occurring in the first trimester are maternal physiological 
changes in the cardiovascular, respiratory, renal, endocrine, and immune systems that enable both 
embryonic development and maternal ability to tolerate the pregnancy (Carlin et al., 2008; Murphy et al., 
2006).  By the end of the first trimester, the embryo has developed into a fetus, which continues to mature 
until delivery.  The maternal physiological changes are maintained during the second (13 to 27 weeks) 
and third trimester (28 weeks until birth).  
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The primary role of the placenta is to support the fetus’ development throughout the pregnancy.  
During the developmental process of the fertilized egg into a baby, signals received cause steady 
modifications in the placental gene expression patterns.  Understanding the proper physiology of placental 
development and different epigenetics mechanisms are critical to improving our knowledge of placental 
epigenetic modifications associated with preterm birth.  
1.3. Human placenta  
The placenta is a structure linking the mother to the fetus.  It transports nutrients and oxygen from 
the mother to the fetus and plays a significant role in transferring carbon dioxide and waste products away 
from the fetus (Ahokas et al., 2008; Gaccioli et al., 2016). 
In humans, the placenta is roughly disk-shaped, and at full term, it measures 22 cm (9 inches) in length 
and slightly 2 - 2.5 cm (0.8 -1 inch) thick and weighs about 500 grams (Burton et al., 2015; Guttmacher et 
al., 2014).  The placenta attaches to the fetus by an umbilical cord of around 55-40 cm (22-24 inches) in 
length, which has two arteries and one vein (Burton et al., 2015; Guttmacher et al., 2014).  During the 
labor process, the placenta is most often delivered (ejected) at the same time as the fetal membranes 
(Benirschke et al., 2012; Zhang et al. 2015).  
The placenta grows along with the fetus during pregnancy, developing along the inside layer of 
the uterus and attached to the fetus by the umbilical cord.  The placenta is also essentially a combination 
of cells from the mother and the growing fetus. Much of the following description of placental 
development is based on the work of many investigators.  The development of the placenta begins upon 
implantation of the blastocyst into the endometrial membrane of the uterus; both fetal and maternal cells 
become combined in the placenta (Benirschke et al., 2012).  The outer cellular layers of the blastocyst 
differentiate into the trophoblast, which forms the outer layer of the placenta.  The trophoblast separates 
into two strata - the underlying cytotrophoblast layer, and the covering syncytiotrophoblast layer.  The 
cover layer integrates into the uterine wall, facilitates fetal-maternal exchanges of blood and nutrients, and 
plays the barrier function of the placenta (Soundararajan and Rao 2004; Starr, 2012; Staun-Ram and 
Shalev, 2005).  
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The placenta acts as a selective filter, permitting some materials to pass (e.g., oxygen, carbon 
dioxide, nutrients, and some viruses) through and holding back others (bacteria, and heparin) depending 
on their mass and form (Huppertz, 2007, LaMar et al., 2003).  In addition to its role of circulating oxygen, 
nutrients, and waste products, the placenta plays an important part in the metabolic and endocrine activity.  
Furthermore, Placenta is involved in producing hormones responsible for sustaining and supporting fetal 
growth and performs biochemical reactions to protect the fetus from exposure to toxicants (tobacco 
smoke, alcohol, chemicals) (Burton et al., 2015; Sood et al., 2006).  Consequently, these environmental 
insults can induce or silent placental genes during development stages (Guo et al., 2008; Kanherkar, et al. 
2014; Sood et al., 2006; Tarrade et al. 2015).  The placenta can thus serve as a record of pathology and 
exposure in the uterus. Some drugs, such as nicotine, cocaine, alcohol, and lead, have been shown to cross 
the placenta (Lewis et al., 2014).  These substances can modify placental gene expression, and some are 
known to accumulate in placental tissue (Bush et al., 2000; Guo et al., 2008; Lewis et al., 2014; Mose et 
al., 2007; Rastogi et al., 2007).  The accumulation of substances can disturb the integrity of the placenta 
and therefore affect the fetus long after delivery (Boekelheide, et al., 2012; Bruin et al., 2010, Vaag et al., 
2014). Vaag et al. (2014) suggested that low birth weight in offspring of women with gestational diabetes 
would have in later life an increased risk of diabetes and cardiovascular outcomes.  Investigations have 
made clear that this process is based on placental epigenetic changes responsible for changing gene 
expression in the developing fetus, and can have health effects in adulthood (Schug et al., 2012). This 
process is explained by fetal programming, a complex process that links environment conditions of the 
placenta during fetal development with adulthood diseases (Maccani et al., 2013; Schug et al., 2012).  
These examples conclude that the placenta is a vital tissue playing a significant role in utero development 
and serving as a record of in utero exposure and later disease.  Therefore, the better understanding of 
placental epigenetic modifications will improve preterm birth, other adverse pregnancy outcomes and our 
ability to prevent and treat later adulthood disorders.  
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1.4. Role of placenta in preterm birth 
The above fact reveals that the placenta plays a vital role in pregnancy.  Therefore, clinicians 
regularly ask pathologists to examine preterm placentae to determine the causes associated with clinical 
history.  Further, the placental examination can provide valuable information to predict long-term 
complications or adulthood diseases.  PTB is a complicated process, and the causes are multifactorial and 
partly understood.  Although contributing mechanisms are unknown, PTB could be the result of placental 
pathogenic influences (Goldenberg et al., 2008; Menon, 2008; Muglia et al., 2010). 
Placental pathology is implicated in two clinical types of preterm birth: spontaneous preterm birth 
(SPB) and indicated preterm birth (IPB).  Goldenberg and colleagues classified SPB into two categories.  
First, premature onset of labor (POL), defined as regular contractions with associated cervical change and 
with intact membranes (40 - 45% of cases of preterm births). Second, preterm premature rupture of 
membranes (PPROM) is the rupture of the amniotic sac (pouch holding fetus and the surrounding fluid) 
before 37 weeks of gestation (25–30% of preterm births) (Goldenberg et al., 2008; Ozer 2013).  Indicated 
preterm birth occurs when labor is induced, or a caesarean section is carried out due to severe impending 
or observed fetal or maternal complications (Ozer, 2013).  Ozer has suggested association of IPB with a 
high occurrence of maternal vascular alterations in the placenta, compared to those described for 
hypertension or placental abruptions (Ozer, 2013). 
1.4.1. Preterm birth and placental pathology  
SPB etiological process can be either infectious (acute or chronic inflammatory pathology) or 
non-microbial (retro membranous hemorrhage, retroplacental or marginal hematoma) (Ozer 2013; 
Romero et al., 2007).  Researchers have suggested that POL can result from (1) acute uterine infection 
(chorioamnionitis), (2) uteroplacental underperfusion (insufficient perfusion of the placenta and the 
uterus), (3) uterine fundal or cervical abnormalities or fetal anomalies (Goldenberg et al., 2008; Romero 
et al., 2007).  Numerous studies found that placentae in PPROM habitually display signs of infection in 
the amniotic fluid or vasculopathic problems including hemorrhage or thrombi (Goldenberg et al., 2008; 
Romero et al., 2007; Steel et al., 2005).  Redline (2008) found that infection of the amniotic fluid has 
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clinical implications for the neonate beyond merely causing preterm birth; for example, an inflammatory 
response associated with cytokine release can cause harm to the developing brain and lungs.  Severe 
uteroplacental underperfusion can be the result of a placental abruption (partial or complete detachment of 
the inner wall of the placenta from the uterus of the mother with internal or external bleeding).  Romero et 
al. (2007) also found chronic uteroplacental underperfusion in pregnancies with maternal chronic 
hypertension or diabetes.  
1.4.1. a. Placental inflammation and infection in PTB 
A considerable body of evidence have suggested that, in addition to POL and PPROM, 
intrauterine infection is a common etiology of SPB (Goldenberg et al., 2008; Redline et al., 2003; Romero 
et al., 2007; Steel et al., 2005).  Intrauterine infection is most prevalent and severe in early preterm 
infants. Romero and colleagues suggested that bacterial infections such as Fusobacterium, Gardnerella 
Vaginitis, and Group B Streptococcus are common and predispose to preterm delivery (DiGiulio et al., 
2012; Romero et al., 2007). 
Investigations of amniotic fluid in SPB have found infections rates of 20-40% (Goldenberg et al., 
2008; Hassan et al., 2014; Ozer, 2013; Romero et al., 2007).  These studies reported positive amniotic 
fluid cultures in 32.5% of women with POL and more than 75% of those with PPROM.  The infections 
can be limited to the decidua (the uterine lining, which forms the maternal part of the placenta) 
(Goldenberg et al., 2008; Ozer, 2013).  However, investigators have suggested that not all women with 
signs and symptoms of chorioamnionitis will have POL or PPROM (Goldenberg et al., 2008).  Also, Ozer 
(2013) established that an essential pathway of SPB seems to include a non-infectious, pathological 
activation of decidual bleeding and inflammation.  Some scientists have found bleeding to be a 
biological/chemical irritant as well as a causal factor of inflammation (Ozer, 2013).  
1.4.1. b. Placental non-microbial etiologies in PTB  
In the absence of infection, the abnormal process of SPB involves a detrimental expression of the 
maternal-fetal hypothalamic-pituitary-adrenal axis (Ozer, 2013).  This process results in the alteration of 
oxytocin balance intrauterine, cortisol levels and the reduction of the ratio of estrogen to progesterone 
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(Benirschke et al., 2012; Ozer, 2013).  Other non-infectious causes of SPB include uterine or cervical 
anomalies such as an abnormally shaped uterus, fibroid growth, a weak or thin cervix (Benirschke et al., 
2006, Ozer, 2013).  Also, the presence of blood behind the placenta and not touching the gestational sac 
may have contributing effects in SPB (Benirschke et al., 2006; Kraus et al., 2004; Ozer, 2013). 
During pregnancy, the placenta goes through cellular differentiation.  Epigenetic mechanisms 
play a part in the regulation of this process.  Therefore, it is necessary to increase our interest in studying 
the epigenetic modifications of the placenta as it provides a mechanism, which can alter the 
developmental process of the fetus. 
1.5. Epigenetic fundamental processes and mechanisms 
Unlike genetics, which describes the actual sequencing of nucleic acids into distinct sections and 
functions.  Epigenetics is a term used to define the mechanisms that lead to variations in the expression of 
genes (Bird, 2007).  Epigenetic modifications can either be inherited mitotically, passing to specialized 
daughter cells in a particular tissue or meiotically through sexual reproduction.  These variations create 
changes in the way a particular gene is expressed, even in exact copies of a gene in different generations 
of a family (Bird, 2007; Dupont et al., 2009).  The epigenetic patterns established in the course of 
development may influence gene expression over a lifetime and increase predisposition to chronic 
disease. 
The field of epigenetics has seen rapid growth over the past few decades, due to advancements in 
molecular biology, biotechnology, and genomics.  As the field continues to grow, there remains a central 
focus of the examination of four principal modes of epigenetic regulation, also shown in the placenta: 
DNA methylation, histone modification, small RNA-mediated control, specifically miRNAs, and 
imprinting.  Further, there is increasing interest in studying the epigenetics of the placenta as it plays a 
significant role in the interaction between maternal-fetal indicators and environmental exposures, and thus 
potential lifelong exposures of the child.   
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1.5.1. Epigenetic mechanisms 
1.5.1. a. DNA methylation 
Four nucleotides form the deoxyribonucleic acid (DNA) - cytosine, guanine, thymine, and 
adenine, arranged in two strands and twisted into the shape of a double helix (Geiman et al., 2010).  DNA 
methylation was the first epigenetic mechanism described in the literature and remains the most widely 
understood process for epigenetic regulation of the genome (Perera et al., 2011; Pozharny et al., 2010a).  
DNA methylation occurs through the addition of a methyl (CH3) group to a cytosine nucleotide (Lim et 
al., 2010).  In the promoter regions of DNA, the addition of this methyl group prevents the binding of 
specific transcription factors to the nucleotide, preventing the production of the gene product and 
effectively silencing the gene. DNA methyltransferases (DNMTs: (DNMT1, DNMT2, DNMT3a, 
DNMT3b, and DNMT3L)) are enzymes that facilitate the addition of the methyl groups (Bird, 2007; 
Jones et al., 2009).  The areas of heavily transcribed DNA tend to be relatively unmethylated while silent 
gene regions tend to be methylated, which strengthened the understanding of the role of methylation 
(Dolinoy et al., 2007). 
At the time of fertilization, genomes experience general genome-wide demethylation (Perera et 
al., 2011).  Consequently, researchers have theorized that DNA methylation is vital to fundamental 
cellular processes, such as gene suppression, X-chromosome inactivation, genomic imprinting (see 
section 1.5.1.d), and proper embryonic development (Bird, 2002; Robertson, 2005; Weber et al., 2007).  
Investigators have linked abnormal DNA methylation to several adverse outcomes, including human 
diseases (Baylin, 2005; Müller et al., 2004).  
1.5.1. b. Histone modification 
Histones are proteins that organize DNA into a compact, round structures known as nucleosomes 
(Youngson and Whitelaw, 2008).  Each nucleosome consists of two structural parts: core histones (H2A, 
H2B, H3, and H4) and linker histones (H1 and H5) (Arya et al., 2010).  DNA wrapped around a cluster of 
eight core histones and bound by the linker histones into the ordered, compressed and structured nuclear 
structures known as chromosomes (Greer et al., 2012; Wood, 2004).  
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Histone modification refers to the addition or removal of chemical groups to or from the histones, 
which can change how and which genes in the nucleosomes are expressed (Greer et al., 2012; Xhemalce 
et al., 2011).  Researchers have described different types of histone modifications, including acetylation, 
methylation, phosphorylation, and ubiquitination (Bannister et al., 2011; Kimura e al., 2004).  
Additionally, a variety of enzymes catalyze these histone modifications, the best understood of which are 
histone methyltransferases (HMTs), acetyltransferases (HATs), kinases and ubiquitylases (Bannister et 
al., 2011; Maccani et al., 2009, Niessen et al., 2009).  Changes to configurations of histone can have many 
negative consequences, including developmental dysregulation, X- chromosome inactivation, and other 
diseases (Calvanese et al., 2008; Xhemalce et al., 2011). 
Histone modifications play a role in various biological processes, such as transcriptional 
activation or inactivation, chromosome packaging, and DNA damage or repair (Xhemalce et al., 2011).  
Studies suggested that the quantification of histone alterations would provide useful information for a 
better understanding of the role of epigenetics in cellular processes and the development of histone 
modifying enzyme-targeted drugs (Dokmanovic et al., 2007; Xhemalce et al., 2011). 
1.5.1. c. Non-coding RNAs  
Non-coding RNAs (Ribonucleic Acid; ncRNAs) are RNA molecules that are copied or 
transcribed from DNA but not translated into proteins (Kaikkonen et al., 2011).  ncRNAs control gene 
expression at the transcriptional and post-transcriptional levels (Collins et al., 2011; Engström et al., 
2006).  ncRNAs also play a significant role in epigenetic regulation.  The two primary groups of non-
coding RNAs involved in epigenetic processes are the long ncRNAs (>200 nucleotides) and the short 
ncRNAs (<30 nucleotides) (Carthew et al., 2009; Kaikkonen et al., 2011).  Further, there are three classes 
of short ncRNA: microRNAs (miRNAs), short interfering RNAs (siRNAs), and piwi-interacting RNAs 
(piRNAs) (Carthew et al., 2009; Kaikkonen et al., 2011; Koerner et al., 2009).  miRNAs are involved in 
genetic imprinting (Cui et al., 2009).  siRNAs participate in mediating post-transcriptional silencing of 
genes (Carthew et al., 2009).  piRNAs are involved in regulating chromatin (DNA and proteins that form 
chromosomes) and suppressing transposon (a slight part of DNA inserted in the genome) activity in 
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germline and somatic cells (Brennecke et al., 2007; Pray, 2008).  It is becoming increasingly apparent that 
ncRNAs play a significant part in histone modification, DNA methylation targeting, and gene silencing 
(Kaikkonen et al., 2011). 
Studies have also found direct involvement of ncRNAs in other cellular processes, such DNA 
rearrangements (Collins et al., 2009; Gangaraju et al., 2009).  There is also evidence of the importance 
specifically of miRNAs in stem cell self-renewal and differentiation (Gangaraju et al. 2009).  Recent 
studies have revealed the role of long ncRNA-mediated epigenetic control systems (Guttman et al., 2009; 
Royo et al., 2008).  For example, X chromosome inactivation (XCI) in female mammals ensures that only 
one of the two X chromosomes in XX females is expressed during development (Engström et al., 2006; 
Koerner et al., 2009; Lee, 2009).  
1.5.1. d. Genomic imprinting 
Genomic imprinting is a manner by which certain genes are expressed in a parent-of-origin 
(Ishida, 2013; Kiefer, 2007; Lobo, 2008; Peters, 2014).  As described above (1.4.1.a), at the time of 
fertilization genomes undergo extensive demethylation to make the genome mostly accessible to the 
developing embryo (Perera et al., 2011).  Mostly, mammal and human offspring inherit two parental 
copies of each gene; however, one of these copies is silenced so that all functions of the gene are 
dependent on the single active copy (Murphy et al., 2003; O’Doherty et al., 2015).  The parent from 
whom the gene is received drives the selective silencing of these genes.  For example, in a female 
embryo, two copies of each same gene are present, one copy from each of her parents.  If this particular 
gene is maternally imprinted, then the paternal copy is silent due to the presence of multiple methyl 
groups in the promoter region and only the maternal copy received from her mother is expressed.  This 
individual will pass on one of her gene copies to her future children, either the actively expressed copy 
from her mother or the inactive copy from her father.  Thus, even if she passes on the inactive copy 
because the gene is maternally expressed, the previously dormant gene will become the actively 
expressed gene copy in her offspring (Murphy et al., 2003; O’Doherty et al., 2015).   
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However, imprinted genes play a significant role in the control of the embryo anatomic and physiologic 
development (physical structures and the nervous system) (Isles et al., 2005; Platonov et al., 2006).  
Epigenetic alterations of imprinted genes can persist for the life of the organism.  Deleterious changes in 
methylation patterns in imprinted genes at conception can lead to life-long diseases, such as Angelman 
Syndrome, Prader-Willi Syndrome, Beckwith-Wiedmann Syndrome (Bird, 2014; Chang et al., 2005; Isles 
et al., 2005).  However, they are reset during egg and sperm formation (Ferguson-Smith et al., 2006; 
Youngson et al., 2008). Nevertheless, whether they came from the mother or the father, individual genes 
can be silenced in the egg, and some in the sperm as well (Ferguson-Smith et al., 2006).  
DNA methylation controls imprinted genes at differentially methylated regions (DMRs) of which 
there are two types (Haycock et al., 2009).  The first category consists of imprinting control regions 
(ICR), which are differentially methylated in all tissues during fetal development.  The second category is 
tissue-specific acquired differential methylation during stages of somatic growth (Haycock et al., 2009). 
1.5.2. Placenta and epigenetic modifications    
In the past decade, researchers have been interested in studying the epigenetic of the placenta, 
especially because placenta provides a mechanism to alter development in response to maternal-fetal 
signals and harmful environmental influences such as cigarette smoke, stress, and air pollution. 
1.5.2. a. Placental DNA methylation  
Normal methylation patterns are vital to many cellular functions, particularly in the placenta 
where correct functioning is critical to fetal growth (Maccani et al., 2009).  After conception, DNA 
methylation of non-imprinted genes goes through a global reprogramming process with active and passive 
phases of demethylation, followed by “de novo” methylation.  De novo methylation is the rearrangement 
of methylation patterns during embryogenesis or differentiation processes in adult cells (Horsthemke et 
al., 2005; Mayer et al., 2000; Peters et al., 2015).  Kim and colleagues examined amnion tissue (inner 
layer of the fetal membranes), from 121 term and preterm births and suggested that DNA methylation 
modifications in the amnion may participate in labor and the etiology of preterm delivery (Kim et al., 
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2013).  This role in the preterm labor is an interesting clue that DNA methylation studies can provide 
insight into the mechanism that contributes to causes of preterm birth. 
In addition to a role in placental function, DNA methylation also affects the physiology of the 
placenta. Researchers have linked maternal vitamin D deficiency to placental DNA methylation 
insufficiency-related complications, such as PTB and preeclampsia (Bodnar et al., 2007; Bodnar et al., 
2015; Knight et al., 2016; Seely, 2007).   
1.5.2. b. Placental histone modifications  
During the blastocyst phase, histone modification plays a significant role in cell differentiation.  
Higher methylation of arginine by the histone H3 causes blastomeres to contribute to the differentiation of 
the embryonic stem cells (Haycock et al., 2009; Torres-Padilla et al., 2007).  This epigenetic difference is 
described by higher histone modification levels in the early growth, compared with the trophoblast 
lineage development (Beaujean et al., 2004; Santos et al., 2003).  However, lower histone modification 
levels in the trophoblast appear crucial for healthy extraembryonic development (Hemberger, 2007).  
Histone modifying enzymes play important roles in the activation of placental-specific genes.  
Chuang and colleagues indicated that histone deacetylase (HDAC) and histone acetyltransferases (HAT) 
are necessary for regulating syncytium, an essential protein involved in the placental formation, thus 
facilitate proper fusion of the trophoblast with the uterine lining (Chuang et al., 2006). Kimura et al. 
(2004) have also noted the role of HAT and histone methyltransferase (HMT) in the regulation of 
placental gene expression.  Research of the effect of histone modification is sparking a better 
understanding of maternal-fetal tolerance as well as placental development and growth. 
1.5.2. c. Placental non-coding RNAs  
Non-coding RNAs hold an important role in facilitating placental epigenetic modifications.  The 
role of ncRNAs in placental development regulation appears to occur through the control of trophoblast 
cell proliferation, migration, invasion, apoptosis, and angiogenesis (Fu et al., 2013).  
Lim and other researchers have published data validating that miRNA expression can occur in the 
tissue of human placenta (Lim et al., 2005; Maccani 2011; Pineles et al., 2007).   These findings imply the 
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usefulness of placental miRNA as clinical biomarkers of diseases. Pineles and colleagues examined 
miRNA levels in placentae and found differential expression of miR-210 and miR-182 in preeclamptic 
placentae compared to normal placentae, advancing efforts to identify a miRNAs biomarker of adverse 
pregnancy outcomes (Pineles et al., 2007).  Donker and colleagues have studied the effects of oxygen 
levels on the epigenetic control mechanisms involved in cell survival and placental growth and found an 
association between oxygen levels and expression of miR-93 and miR-424 in the trophoblast (Donker et 
al., 2007). Such Findings may provide pathologists a sensitive tool to understand and detect adverse 
pregnancy outcomes and investigate whether the results vary at particular windows of fetal development 
(Cox et al., 2015, Donker et al., 2007). 
1.5.2. d. Placental imprinting  
Genomic imprinting plays a significant role in fetal development and placental biology (Maccani 
et al., 2009, Moore et al., 2015).  Tycko has found an overestimation of the control of allelic expression in 
the placenta, and an association between imprinting modifications and placental pathologies (Tycko, 
2006).  Various studies have found the implication of imprinting alterations in placental-related 
pathologies such as preeclampsia and prematurity (PROM, PPROM) (Guo et al., 2008; Jansen et al., 
2015; Lambertini et al., 2008).  
In anticipation of finding new biomarkers affected by environmental exposures, investigators have 
studied patterns of imprinting in the human placenta (Guo et al., 2008; Lambertini et al., 2008).  
Lambertini and colleagues have shown that loss of imprinting (LOI) is common in the human placenta, 
and have become an important biomarker for epigenetics-related prenatal conditions (Lambertini et al., 
2008).  Also, investigation of gene expression and methylation patterns of imprinting regions in SGA by 
Guo et al. (2008) have shown that LOI at H19 (imprinted maternally expressed transcript-non-protein 
coding) is related to methylation modifications, and subsequent effects on gene expression may be a 
contributing cause of fetal growth limitation. Imprinted genes such as PEG10 (Paternally Expressed Gene 
10) and PHLDA2 (Pleckstrin homology-Like Domain, Family A, Member 2) play crucial roles in 
placental morphology and function (Ishida et al., 2012; Lewis et al., 2012; McCullough et al., 2016).  
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Cleveland and others have suggested the involvement of insulin-like growth factor 2 (IGF2) in the 
regulation of placental nutrient source (Angiolini et al., 2006; Cleveland et al., 2016). Pozharny and 
colleagues have found a higher rate of LOI in preterm placentae compared to term placentae (Pozharny et 
al., 2010b).  
A study of relations of altered patterns of expression of imprinted genes by McMinn and 
colleagues compared intrauterine growth restricted (IUGR) and non-IUGR placentae.  They concluded 
that differential expression of a particular panel of imprinted genes might be a possible biomarker for 
IUGR (McMinn et al., 2006). 
These results suggest that various factors related to pregnancy outcomes such as PTB, IUGR, and 
SGA may influence imprinting control mechanisms in the placenta.  More research is needed to 
understand better the mechanisms of imprinting in the placenta and their impact on fetal growth and 
development, specifically PTB. 
1.6. Maternal factors, epigenetics and PTB 
The present section aims to examine the link between maternal factors, epigenetics mechanisms, 
and PTB.  The key components involved in epigenetics regulation are DNA methylation, histone 
modifications and changes in micro ribonucleic acids (miRNA) (see above section 1.5).  Epigenetic 
changes are a reversible system and affected by various maternal characteristics and diseases (Feil et al., 
2012; Gabory et al., 2009; Jelliffe-Pawlowski et al., 2015; Lynch et al., 2014, Russ et al., 2014 Tarry-
Adkins et al., 2011).  Maternal behaviors and living conditions determine the environmental factors 
affecting her offspring.  The prenatal environment affects epigenetic mechanisms making them 
potentially important pathogenic mechanisms in complex multifactorial adverse pregnancy outcomes such 
as PTB, preeclampsia, and small for gestational age (Nieuwenhuijsen et al., 2013). 
A comprehensive review by Aguilera and colleagues yielded a list of maternal factors affecting 
epigenetics mechanisms.  These factors are age, race, diet (folate intake), high body mass index, diabetes, 
hypertension, unhealthy behaviors (alcohol, tobacco, and drug use), and living or 
workplace/neighborhood conditions (Aguilera et al., 2010).  We developed a causal diagram to make 
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inference between environmental factors, epigenetics mechanisms, and PTB, and to assess the causal 
relationship between the three elements (Figure 1 and 2).  
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Figure 1. Causal diagram of factors affecting PTB 
The causal diagram shows a possible scenario between maternal factors (MF) effect on epigenetic 
mechanisms (EM) and pregnancy outcomes (PO).  
 
Figure 1 presents a simple causal relations diagram of the main principal risk factors and their influence 
on each other.  The single-headed arrows show the directional effect of one factor on another.  Maternal 
factors, which determine the environment insults to which the offspring is affected have a directed effect 
on epigenetic mechanisms and pregnancy outcomes.  The diagram also displays the influence of 
epigenetic mechanisms on pregnancy outcomes. 
 
 
Maternal factors (MF) (race,
age, stress, addictive
substances, diabetes,
hypertension, infections/
sepsis)
Epigenetics mechanisms (EM)
(DNA methylation, histone
modifications and miRNA)
Pregnancy outcomes (PO)
(Preterm birth)
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Figure 2. Causal risk factors of preterm birth 
Figure 2 expands the model with the main causal factors.  The same system elements are included in 
mapping maternal factors (e.g., maternal characteristics and living conditions), epigenetics alterations 
(e.g., DNA methylation, histone modification, and miRNA alteration). Maternal level elements are shown 
on top, and epigenetics levels are in green and on the left. The single-headed arrows indicate the 
directional effect of one variable on another (e.g., maternal age has a direct effect on epigenetic 
mechanisms and PTB, on a diet, which has a direct effect on diabetes and hypertension).  
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1.7. Conclusion  
Increasing knowledge of epigenetic shows that biologic inheritance is more complicated than 
genetics alone.  Epigenetic connects environmental factors (behaviors, diet, lifestyle, exercise) and health 
of an individual, and genetic impacts on the traits of a person.  Epigenetic research is supporting the 
conclusion that environmental and parental factors can make changes to genetic material (without 
affecting the DNA sequence) that influences health throughout the life of an individual, and transmits to 
offspring, setting the groundwork for the theory of life-course in preterm labor.  Life-course principles 
focus on the idea that health outcomes are due to a complex interaction of parental and environmental 
factors across a course of an individual’s life.  Thus, interventions to improve preterm births should focus 
on understanding epigenetics across the human lifespan to improve personalized medicine.  
This chapter further our knowledge of the critical role of epigenetic modifications (DNA 
methylation, histone modifications, miRNA and mRNA expressions, and imprinting) in placental 
reprogramming and the molecular mechanisms of this multifactorial disease named preterm birth.  
Understanding the role of placental epigenetic changes in PTB is clearly essential for the development of 
effective methods of diagnostics, prevention, and treatment.   
In some, epigenetics is at the intersection of basic science, clinical medicine, and public health. 
Increasing knowledge in this emerging field has the potential to help understand the role of placental 
epigenetic alterations in premature births that currently face societies around the world and to find 
epigenetic biomarkers to further the early diagnosis, prevention, and treatment. 
The following chapter assesses evidence from published, peer-reviewed epigenetics studies examining the 
link between human placenta epigenetic alterations and PTB to find genes of causal importance. 
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Abstract 
Objective: Preterm birth (PTB) is one of the leading causes of neonatal mortality and morbidity around 
the world. Epigenetic alterations of the human placenta may be involved in the causal chain of adverse 
pregnancy outcomes specifically PTB. In this systematic review, we investigated whether epigenetic 
dysregulation of the human placenta is associated with PTB. 
Methods:  We searched MEDLINE and EMBASE and systematically reviewed all relevant studies on 
epigenetic placental modifications in PTB. Two independent reviewers selected controlled human studies 
published in any language, evaluated their quality, and graded them using the Newcastle-Ottawa Quality 
Assessment Scale. We resolved disagreements by consensus with a third reviewer. 
Results:  Eleven observational studies of low to moderate quality met the eligibility criteria out of 60 
unique studies. Most studies reported an association between placental epigenetic changes (methylation, 
mRNA and miRNA) and PTB, although research methods were highly heterogeneous. 
Conclusions: Studies reported various associations between specific epigenetic findings and PTB, 
although methodological concerns limited results validity. Additional high quality studies are needed to 
assess the repeatability of these findings. The STROBE guidelines can be used to improve the quality of 
reporting.   
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Introduction 
Preterm birth (PTB) is defined as giving birth before thirty-seven completed weeks of gestation 
(World Health Organization, 2016). PTB is the primary cause of neonatal morbidity and mortality in the 
United States (Hamilton et al., 2012).  
The placenta plays a vital role in fetal growth and development through the transfer of nutrients 
and waste, and in protecting the fetus from environmental insults (Robins et al., 2011).  Deficiencies in 
the development and role of the placenta have been associated with adverse pregnancy outcomes 
including PTB, intrauterine growth restriction (IUGR), and preeclampsia (PE) (Kulkarni et al., 2011). 
Epigenetics is the study of processes that produce changes in gene activity and expression without 
altering the DNA sequence (Bird, 2007). Epigenetic changes include DNA methylation, histone 
modification, microRNA actions, and imprinting (Egger et al., 2004). These changes may last through 
several cell divisions for the duration of a cell's life, and may last for several generations, although they 
do not involve changes in the underlying DNA sequence (Bird, 2007). 
Pregnancy is a period during which epigenetic alterations are active. Embryonic and fetal growth 
processes depend on complex interactions between genetic, epigenetic and environmental factors 
(Maccani et al., 2013). During pregnancy complications, epigenetic changes play a role in altering 
placental patterns of fetal growth or phenotypes (Boyd et al., 2009; Gheorghe et al., 2010).  
Placental genetic and epigenetic profiles might serve as markers of the intrauterine and extra 
uterine environment (Filiberto et al., 2011; Nelissen et al., 2011).  For example, studies found that 
offspring of Dutch famine survivors exposed to starvation early in gestation had lower levels of DNA 
methylation of the insulin-like growth factor II (IGF2) gene compared to their unexposed same-sex 
siblings (Heijmans et al., 2011). Histone modifications may be involved in cell reaction to environmental 
stresses (Burkhart et al., 2008). These modifications alter gene expression via post-replication chromatin 
assembly using histone methyltransferases (HATs), histone acetyltransferases (HMTs), histone 
deacetylases (HDAC), and histone demethylases (HDMs) (Munshi et al., 2009). Lastly, miRNAs, given 
their profile of activity in facilitating control of gene expression in vertebrates, are excellent candidates 
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for the molecular basis of epigenetic programming. Researchers found that altered patterns of miRNA 
expression in placentas are associated with preeclampsia (Pineles et al., 2007).  
However, it is not clear whether the published literature supports an association between placental 
epigenetic modifications and PTB. Thus, we conducted a systematic review to evaluate available 
evidence from published, peer-reviewed epigenetics studies examining the association between human 
placental epigenetic alterations and PTB.  
Methods 
We reviewed the published literature to address the following question: Is there an association 
between human placental epigenetic modifications and PTB? We systematically searched two electronic 
databases, PUBMED and EMBASE (up to November 9, 2015). To identify relevant articles we used the 
following keywords: placenta AND (epigenetic OR DNA methylation OR microRNA OR miRNA OR 
histone OR acetylation) AND preterm birth (Supplemental Tables S1 – S2). We assessed additional 
studies by reviewing the reference lists of identified articles. Eligible articles were controlled human 
studies with PTB as the outcome and placenta as the tissue of interest, with no language restrictions.  
We initially used built-in database filters to exclude case reports, editorials, conference abstracts, 
and reviews. Then, two reviewers independently reviewed articles’ title, abstract or full text. Studies were 
excluded if they were duplicates, editorials, conference abstracts, not relevant (tissues other than placenta 
or no epigenetic alterations), or did not report PTB results for either the exposed or the concurrent 
comparison groups. We solved disagreements in study selection through consensus with a third reviewer.    
The two reviewers also individually extracted and assessed the following information from 
eligible full-text articles using a standardized process:  author and year of publication, study design, 
sample size and characteristics, exposure, outcome, statistical analysis, results bias and grading. We 
solved disagreements in data extraction by discussion and consensus with a third reviewer.  
Finally, two reviewers independently rated the methodological quality of each study. The Critical 
Appraisal Skills Program (CASP) tool was used to guide the initial qualitative assessment. The 
Newcastle-Ottawa Quality Assessment Scale (NOS) was then used to calculate a numeric quality score 
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ranging from 0 (low) to 9 (high) (CASP, 2007; Wells et al., 2016). We solved disagreements by 
consensus with a third reviewer. We contacted authors as needed for clarifications when discrepancies 
were found compared to other published literature.    
Results  
Initial electronic searches of EMBASE and PubMed yielded 74 articles. After removing 14 
duplicate studies common to both databases, we excluded 40 additional studies through the automated 
filters. Lastly, we removed nine studies following title, abstract or full-text review (Figure 1).  
Eleven studies published between 2009 and 2015 remained for quality assessment (Table 1). All 
selected publications were in English, although there were no language restrictions. Nine studies used a 
case-control design (Anton et al., 2010; Dhobale et al., 2013; Enquobahrie et al., 2015; Kim et al. 2013; 
Kulkarni et al., 2011; Mayor-Lynn et al. 2011; Montenegro et al., 2009 Shimanuki et al., 2015 Sundrani 
et al. 2014) and two employed a cross-sectional design (Lee et al., 2011; Maccani et al., 2013). Five of the 
studies were conducted in North America, four in Asia, one in South America, and one in an 
undetermined location.  Dates of participants’ recruitment ranged from 2005 to 2014. However, five 
studies did not report the recruitment period.  
The source population was often not well defined, unclear or unknown (Enquobahrie et al., 2015; 
Lee et al., 2011; Montenegro et al., 2009; Pineles et al., 2007) and at times, it differed markedly for cases 
and controls (Mayor-Lynn et al., 2011. Participant recruitment methods and percent refusal were not 
reported. In four studies, the number of participants was not clear or variable depending on the hypothesis 
tested (Dhobale et al., 2013; Kim et al., 2013; Mayor-Lynn et al., 2011; Sundrani et al., 2014). In the 
remaining studies, the total number of participants ranged from 10 to 221. None of the articles included a 
sample size justification. There was significant heterogeneity in participants’ eligibility criteria across 
studies. Basic demographic and clinical characteristics of the study samples were sometimes unclear or 
not reported.  
The specific methods used to ascertain the outcome of interest, PTB, were not always reported Anton et 
al., 2010; Mayor-Lynn et al., 2011; Montenegro et al., 2009; Shimanuki et al., 2015; Sundrani et al., 
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2014). In one study, PTB could not be entirely distinguished from preeclampsia because all preterm cases 
and only some of the term controls had preeclampsia (Anton et al., 2010). The placental tissue was 
typically collected at the time of delivery, although in some cases the time of collection or length of 
storage was not defined or differed across studies. In two studies, placentae were obtained from an 
existing tissue bank. Many studies used the whole placenta tissue while others examined the chorion vs. 
amnion. Most studies did not explicitly state quality control procedures. 
All studies were focused on three epigenetic mechanisms: miRNA expression, mRNA expression 
and DNA methylation. None of the studies assessed histone modifications or imprinting. Diverse 
laboratory techniques and statistical tests were used for the analysis of the source tissue. To ascertain 
miRNA or mRNA-related epigenetic changes, six studies used only RT-qPCR (Anton et al., 2010; 
Dhobale et al. ,2013; Enquobahrie et al., 2015; Kim et al., 2013; ; Lee et al., 2011; Sundrani et al., 2014), 
whereas two studies used RT-qPCR combined with other methods (Mayor-Lynn et al., 2011; Montenegro 
et al., 2009).  
For DNA methylation, most of the studies were candidate gene-based except for one study that 
used a genome-wide approach (Kim et al., 2013). Five studies measured DNA methylation using various 
techniques: genome-wide methylation, bisulfite sequencing and methylation specific polymerase chain 
reaction (Kim et al., 2013), ELISA-like reaction (Kulkarni et al., 2011), pyrosequencing Maccani et al., 
2013), Sequenom mass ARRAY EpiTYPER (Sundrani et al., 2014), or Sensitive Methylation Specific – 
PCR (Shimanuki et al., 2015).  
Except for one study in which laboratory investigators were blinded (Kim et al., 2013), none of 
the studies reported the use of blinding strategies during different study phases to minimize bias. Data 
entry, management and quality control procedures were not described. Moreover, most of the studies 
performed limited or no adjustment for confounders, or reported incomplete results (i.e., some estimates, 
variances or test results were missing). Overall, the studies included in our review were of low to 
moderate quality. All studies scored 6 or lower on the Newcastle-Ottawa Scale, with 8 (67%) studies 
scoring 4 or less out of a maximum score of 9.  
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The eleven selected studies investigated the association between PTB and three epigenetic alterations 
(miRNA, mRNA regulation, DNA methylation) and the majority did find an association. In addition to 
the global DNA methylation, eight candidate genes (UCN, OXTR, RUNX3, VEGF, KDR, FLT1, DLL1 
and NOTCH 1) were assessed for methylation levels in the studies included in this review (Table 2). 
UCN, OXTR, DLL1 and RUNX3 were hypermethylated in preterm versus term placentae, although, only 
one RUNX3 CpG site out of seven was methylated (Maccani et al., 2013). There was no difference in 
overall methylation of VEGF, KDR, and FLT1 promoter methylation. However, there were individual 
CpG sites that showed differential methylation between the term and preterm groups (Sundrani et al., 
2014). There was no methylation of NOTCH1 in either group Shimanuki et al., 2015). 
Five studies investigated the mRNA expression of eighteen genes (Table 3). The mRNA expression levels 
of three genes (KDR, OXTR and UCN) were higher in preterm vs. term placentae, although two of the 
mRNA (OXTR and UCN) were only upregulated in amnion, not in chorion tissue. The mRNA expression 
of three genes (BDNF, NGF, and VEGF) was lower in preterm vs. term placentae. The remaining genes 
did not show differences in mRNA expression levels.  
The review included five studies of twenty candidate miRNAs (Table 3). When comparing 
preterm versus term placentae, twelve miRNAs were upregulated, and seven were not differentially 
expressed. In addition, expression of one (miRNA-210) of the twenty miRNAs was reported in three 
separate studies: Lee reported downregulation in preterm vs. term placentae, Mayor-Lynn reported no 
change, and Enquobahrie reported downregulation in preterm vs. term amnion and no difference in 
preterm chorion (Enquobahrie et al., 2015; Lee et al., 2011; Mayor-Lynn et al., 2011).  
Overall, epigenetic findings were unique, with little overlap across studies in the types of 
candidate genes, mRNA and miRNA selected for analysis. Research methodology, such as study design, 
sample size and analytical approaches also differed across studies. Some studies identified differential 
placental epigenetic changes between preterm and term groups.  
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Discussion  
We performed a systematic review of the literature on placental epigenetic modifications 
associated with preterm birth and identified eleven eligible studies. There was heterogeneity in study 
design, clinical, laboratory, and analytical approaches. Most studies had design or analysis concerns that 
reduced the validity and precision of their results. 
Methodological approaches differed substantially across studies. None of the studies reported all the items 
in the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) checklist, a 
widely-used reporting guide for clinical and epidemiologic research studies (von Elm et al., 2008). 
Although the studies in this review had a primary basic science focus, they also included an underlying 
clinical and population-based component. Thus, following the STROBE guidelines would have 
strengthened their reporting quality.  
Most study designs were hospital-based case-control or cross-sectional studies. The primary study 
hypothesis did not always focus on the association between epigenetic alterations and PTB. For this 
reason, some of the techniques, results and reporting were not considered as robust as they could have 
been, which affected the NOS quality score (Wells et al., 2016). 
The source population was not always described, especially when a tissue bank was used. For 
example, the year (s) during which the study was conducted was often missing, and the source population 
for cases and controls appeared to differ, leading to comparability concerns and potential selection bias 
(Mayor-Lynn et al., 2011). Eligibility criteria were ill-defined in some studies. The lack of statistics on 
the source population and sample selection procedures limited readers’ ability to assess study 
generalizability and to make inferences.  
Sample size varied considerably among studies, ranging from 10 to 221. Also, none of the studies 
included power calculations. The small sample size of some studies increased the likelihood of their 
findings being dependent on random error (Akobeng, 2016). 
The selected studies exhibited considerable clinical heterogeneity, e.g., differences in delivery modes 
(cesarean or vaginal).  Delivery methods might have affected epigenetic alterations that were not directly 
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involved in PTB (Almgren et al., 2014).  There was also substantial heterogeneity across studies in the 
types of placental tissues studied. The maternal-fetal interface is complex and different tissues in the 
placenta have distinct roles and function. There is no consensus yet in the literature as to which tissues are 
most appropriate for epigenetic studies (e.g., amnion versus chorion).  
All but one of the studies were candidate gene-based (Kim et al., 2013). Given the early stage of 
epigenetic research, genome-wide studies would have been valuable in exploring the entire gene system, 
although they would have required larger sample sizes and independent replication (Johnson et al., 2010). 
Candidate genes differed across studies and, even for the same genes, different regions or regulatory 
mechanisms were assessed. For example, some of the studies focused on the promoter region or a limited 
number of CpG sites. 
Incomplete methods reporting did not allow an assessment of how study results might have been 
affected by the timing of sample collection, tissue storage conditions, or the specific laboratory tests used. 
Improving standardization and clarity across studies regarding these different laboratory approaches 
would improve readers’ ability to interpret results, understand study limitations, and draw appropriate 
conclusions. The use of techniques such as investigator blinding could have minimized potential bias.   
A major weakness of most analyses was that only crude results were reported. The incomplete 
measurement and analysis of potential confounders (e.g., maternal smoking), the lack of clarity of how 
some variables (e.g., preterm birth) were defined or collected, and inconsistencies in the presentation of 
results (e.g., tables and text did not match) weakened the studies’ internal validity.  
A limitation of this systematic review was the inability to perform a meta-analysis, due to the 
studies’ substantial clinical and biological heterogeneity, e.g., different number of genes and gene regions 
reported, with minimal overlap across studies. Additionally, there was substantial heterogeneity of 
methods used across studies, such as differences in source populations, clinical data collection, laboratory 
assays and analytical approaches.  
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Conclusion 
Confirmation of placental epigenetic differences in preterm vs. term birth could suggest potential 
screening, diagnostic or therapeutic targets. In this systematic review, we identified a number of studies 
reporting an association of PTB with differential expression of miRNAs and mRNAs, and DNA 
methylation status. However, extensive concerns about bias, heterogeneity, and limited reproducibility 
reduced the strength of evidence derived from these studies.  This review highlights the need for 
epigenetic studies to use rigorous, standardized and unbiased research methodologies, and for journals to 
require a higher standard of quality reporting.  
These findings will help to improve our understanding of interactions between placenta and 
epigenetic modifications, as well as to improve epigenetic studies yielding to find epigenetic biomarkers 
for the diagnosis and treatment of PTB. Such epigenetic biomarkers will be useful if women at risk of 
PTB and related pregnancy complications are identified. Thus, chapter 3 will assess maternal risk 
predictors of PTB.   
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 Figure 1 Flow chart of literature search. 
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Duplicates 
n=14 
Excluded by automated 
filters 
n=40 
(1 case report, 16 
editorials/conferences 
abstract, 20 reviews,        3 
non-humans) 
Unique articles available 
for review 
n=60 
Manual exclusion after full-text 
review 
n=6 
(Reviews, case/reports /case series, 
editorials /meeting abstracts, non-
human, not relevant, results not 
reported, no concurrent controls, no 
epigenetic alterations, no placenta) 
Full-text articles assessed 
for eligibility 
n=17 
Studies included in qualitative 
synthesis 
n=11 
Manual exclusion after title 
and abstract review  
n=3 
(Reviews, case reports/case 
series, editorials/meeting 
abstracts, non-human, not 
relevant) 
Keywords for: Epigenetics, 
Placenta, Preterm 
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Table 1. Characteristics of studies included in the systematic review of placental epigenetic modification and preterm birth.  
Author, 
Year  
Study 
Design 
Sample Epigenetic 
Mechanism 
Outcome of 
Interest 
Statistical 
Analysis 
Results Bias & Grading 
Anton et al., 
2015  
[18] 
Hospital 
based case- 
control study 
Place/year: Pennsylvania, USA; 
2005-2009 
Eligibility: Newborns from 
women with no HTN or with PE 
defined according to ACOG 
standard. 
Cases: preterm  
Controls: term  
Sample size: 27  
 
miRNA (miR-
517a/b and 
miR-517c) 
Ascertained: 
RT-qPCR 
Preterm birth 
(GA <37 weeks 
vs. GA ≥37 
weeks) 
Ascertained: 
Not specified 
t-test; or 
ANOVA 
followed by 
Student-
Newman-Keuls 
(SNK) test; or 
Mann-Whitney 
test 
miR-517a/b was significantly up-regulated 
in cases (p = 0.0060) vs. controls; miR-
517c was significantly up-regulated in 
cases vs. controls (p = 0.0098). 
Design: Eligibility criteria ill-defined. 
Blinding, and non-response rate 
unknown. Recruitment methods and 
data management not described. 
Analysis: No power analysis, small 
sample size and no adjustment for 
confounders.  
NOS : S=1, C=0, E=2 (Total=3) 
Dhobale et al., 
2013 
[19] 
 
 
Hospital 
based case-
control study 
Place/year: Pune, India; 2009-
2011 
Eligibility: Newborns from 
women with no complications 
and no history of alcohol or drug 
abuse 
Cases: preterm 
Controls: term 
Sample size: Variable (n=53-75)  
 
mRNA (BDNF 
and NGF) 
Ascertained: 
RT-qPCR 
Preterm birth 
(GA <37 weeks 
vs. GA ≥37 
weeks) 
Ascertained: 
LMP plus 
Ultrasound 
Student’s t-test, 
partial 
correlation 
method 
BDNF and NGF mRNA levels were lower 
in the preterm group as compared to the 
term group (p < 0.05).  
There was a positive association between 
BDNF mRNA levels (r = 0.236, p = 
0.049) and NGF mRNA levels (r = 0.256,   
p = 0.064) with GA. 
Design: Eligibility criteria ill-defined. 
Blinding and non-response rate 
unknown. Data management not 
described. 
Analysis: no power analysis  
NOS : S=2, C=2, E=2 (Total=6) 
Enquobahrie et 
al., 2015  
[20] 
 
 
 
 
Hospital 
based case-
control study 
 
 
 
 
 
Place/year: Seattle, Washington, 
USA, year unknown. 
Eligibility: Newborns from 
women with no history of 
diabetes, chronic HTN, or 
clinical chorioamnionitis 
Cases: preterm (sPTL-PTD, 
PPROM-PTD, PE-PTD) 
Controls: term   
Sample size: n= 40 (4 groups) 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
mRNA  
(MMP-2, 
MMP-9,  
TIMP-1) 
miRNAs 
(miR-199a, 
202, 210, 214, 
223, 338)  
Ascertained: 
RT-qPCR 
Preterm birth 
(GA <37 weeks 
vs. GA ≥37 
weeks).  
Ascertained: 
LMP plus 
Ultrasound 
Multinomial 
logistic 
regression  
In the amnion, across the 4 groups, there 
was an overall difference in expression of 
MMP-9 (p=0.0092), miR-210 (p=0.0039) 
and miR-223 (p=0.0400) adjusted for age 
and mode of delivery. However, there 
were no pairwise differences in 
mRNA/miRNA for any of the groups vs. 
controls except that expression of miR-
210 was lower for the PE-PTD group vs. 
the term group (“RRR”: 0.45; 95%   CI: 
0.22-0.91). Results for MMP-2 and TIMP-
1 were not reported. In the chorion, there 
was no association of mRNA or miRNA 
expression with PTD. 
 
 
 
 
 
 
 
Design: Source population unclear, 
eligibility criteria ill-defined. Blinding 
and non-response rate unknown.  
Analysis: no power analysis, small 
sample size, odds and odds ratios 
interpreted as risk and risk ratios, 
overall p-value used to refer to group 
wise comparisons, limited adjustment 
for confounders.  The mRNA listed in 
the table of results do not match those in 
the methods and analysis sections.  
NOS : S=2, C=1, E=2 (Total=5) 
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Author, 
Year 
Study 
Design 
Sample Epigenetic 
Mechanism 
Outcome 
of Interest 
Statistical 
Analysis 
Results Bias & Grading 
Kim et al., 2013 
[21] 
 
 
 
 
 
 
Multicenter, 
hospital-
based case 
control study 
Place/year: Iowa, USA and 
Tucuman, Argentina; 2009-
2010. 
Eligibility: No exclusions 
stated  
Cases: spontaneous preterm  
Controls: term cesarean and 
vaginal delivery 
Sample size: Unclear. Some 
samples added midway. 
DNA 
methylation/ 
mRNA  
(OXTR and 
UCN) 
Ascertained: 
Genome-wide 
DNA 
methylation, BS, 
MSP, and RT-
qPCR 
Preterm birth 
(GA <37 
weeks vs. GA 
≥37 weeks) 
 Ascertained: 
LMP & 
Ultrasound 
  
 
t-test, Mann-
Whitney rank 
sum test, one-
way ANOVA, 
or Kruskal-
Wallis, one-
way ANOVA 
by rank, and 
pairwise 
comparisons 
UCN was one of 61 autosomal genes 
differentially methylated between the PTL and 
TL groups (score difference of >30; 𝑃<0.001). 
BS validation showed no difference in UCN 
methylation between PTL vs. TL (p>0.05). For 
OXTR, 3 out of 6 CpG sites (in either amnion or 
decidua tissue) were differentially methylated 
among the three groups (p<0.02). There was an 
increase in UCN and OXTR mRNA levels in the 
PTL vs. TL amnion (p<0.05) but not decidua 
samples. 
 
Design: Eligibility criteria ill-
defined, limited generalizability. 
Blinding and non-response rate 
unknown. Data management not 
described. 
Analysis: No power analysis, 
sample size unclear, no adjustment 
for confounders, multiple 
comparisons  
NOS : S=2, C=0, E=2 (Total=4) 
Kulkarni et al., 
2011 
[4] 
Hospital 
based case-
control study 
Place/year: Pune, India; 2007-
2009 
Eligibility: Newborns from 
women without certain 
systemic diseases. No 
alcohol/drug abuse. 
Cases: preterm PE  
Controls: term normotensive 
and PE 
Sample size: n= 57  
Global DNA 
methylation 
Ascertained: 
ELISA-like 
reaction 
 
Preterm birth  
(Not defined) 
Ascertained: 
LMP & 
Ultrasound 
ANOVA Mean global DNA methylation levels were 
significantly higher in the PTPE group (0.72% ± 
0.37%, p<0.05) relative to the normotensive term 
(0.53% ± 0.24%) group. “Although there is 
increased methylation in preterm pre-eclampsia 
when compared with normotensive pregnancies, 
the difference is not statistically significant.” 
Design: Limited generalizability. 
Blinding and non-response rate 
unknown. Data management not 
described. 
Analysis: No power analysis, 
matching method unclear, analysis 
does not account for matching, no 
adjustment for confounders. 
Inconsistent results.  
NOS: S=0, C=0, E=2  (Total=2) 
 
Lee et al., 2011 
[26] 
 
 
Hospital 
based cross- 
sectional 
study within 
a case-
control  
Place/year: Santiago, Chile; 
year unknown. 
Eligibility: Not stated 
Sample size: n= 221 
 
miRNA  
(miR-210) 
Ascertained: 
RT-qPCR 
Preterm birth 
(no cutoff; 
continuous 
GA) 
Ascertained: 
Sonography 
No test 
reported 
Placental expression of miR-210 was 8.6% 
higher for every week of GA in patients without 
PE, whereas it was 5.0% lower for every week of 
GA in patients with PE.  
 
Design: Source population and 
eligibility criteria ill-defined, 
limited generalizability. Blinding 
and non-response rate unknown.  
Recruitment methods and data 
management not described. 
Analysis: No power analysis, no 
statistical test  
NOS : S=2, C=0, E=2 (Total=4) 
 
Maccani et al., 
2013 
[7] 
Hospital 
based cross-
sectional 
study 
Place/year: Providence, 
Rhode Island, USA; 2008-
2009. 
Eligibility: Unclear 
Cases: preterm 
Controls: term  
Sample size: n=206 
DNA 
methylation 
(RUNX3) 
Ascertained: 
Array with 
pyrosequencing 
for selected 
samples and CpG 
loci 
 
 
 
 
 
Preterm birth 
(GA <37 
weeks vs. GA 
≥37 weeks) 
Ascertained: 
Sonography 
Logistic 
regression 
Methylation at one (cg04757093) out of 7 
RUNX3 loci was associated with PTB (OR: 10.2, 
95% CI: 1.1– 103.3; p < 0.04) after adjustment 
for major confounders. 
Design: Eligibility unclear (all 206 
participants in the original study 
had GA≥36, though in this study 
minimum GA=28). Limited 
generalizability. Blinding and non-
response rate unknown. Data 
management not described.  
Analysis: No power analysis. 
NOS: S=2, C=2, E=2 (Total=6) 
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Author, 
Year 
Study 
Design 
Sample Epigenetic 
Mechanism 
Outcome 
of Interest 
Statistical 
Analysis 
Results Bias & Grading 
Mayor-Lynn et 
al., 2011 
[22] 
Hospital 
based case-
control study 
Place/year: Gainesville, 
Florida, USA; year unknown. 
Eligibility: Newborns from 
women without: diabetes 
mellitus, PPORM without 
labor, multiple gestations, fetal 
demise in utero or fetal 
anomalies. 
Cases: spontaneous PT 
Controls: NT with C-section 
Sample size: variable (n=10-
21) 
miRNAs and 
mRNAs 
(multiple) 
 
Ascertained: 
Array and RT-
qPCR  
Preterm birth 
(GA ≤35 
weeks vs. GA 
>35 weeks) 
 
Ascertained: 
Not specified 
 
“R” analyses 
and t-test/ 
ANOVA  
None of the miRNA (miR-15b, -181a, -200c, -
210, and -483-5p, miR-296 and miR-493) 
selected for RT-qPCR validation following the 
array had a significantly different expression 
across groups. mRNA expression of related 
genes (SOCS1, ADAM17, TIMP3, CRH, 
CRHBP, ADAM30, MMP1, MMP9 and STC2) 
was not significantly different across groups. 
Design: Different source population 
for cases and controls. Limited 
generalizability. Blinding and non-
response rate unknown. 
Recruitment methods and data 
management not described.  
Analysis: No power analysis, small 
sample size, no adjustment for 
confounders. Multiple comparisons. 
Disagreement in results between 
figures and supplemental tables. 
NOS : S=1, C=0, E=2 (Total=3) 
 
Montenegro et 
al., 2009 
[23] 
Hospital-
based case-
control study 
Place/year: Unknown 
Eligibility: Tissue samples 
from placentae free of 
histopathologic lesions. No 
medical, surgical or obstetric 
complications. 
Cases: preterm labor 
Controls: term (labor or no 
labor)  
Sample size: n=30 
miRNA  
(9 miRNAs) 
 
Ascertained: 
Array followed 
by RT-qPCR 
Preterm birth 
(GA <37 
weeks vs. GA 
≥37 weeks) 
 
Ascertained: 
Not specified 
Moderated t-
test with FDR 
correction, and 
t-test 
 
In transcriptome analyses, nine miRNA (miR-25, 
338, 101, 449, 154, 131a, 142-3p, 202*, 136) 
were down-regulated in term labor or no labor vs. 
preterm labor.  
Four miRNA (miR-338, -449, -136, -199a*) were 
overexpressed in preterm vs. term labor in both 
the array and RT-qPCR analyses (p<0.05). RT-
qPCR results were not reported for the 
comparison between preterm labor and term no 
labor controls. 
 
Design: Source population 
unknown, eligibility criteria ill-
defined. Blinding and non-response 
rate unknown. Recruitment methods 
and data management not described. 
Analysis: No power analysis, 
multiple comparisons. 
NOS : S=1, C=0, E=2 (Total=3)  
Shimanuki et 
al., 2015 
[24] 
Hospital 
based case-
control study 
Place/year:  
Tokyo, Japan; 2011-2014 
Eligibility:  
No exclusion criteria stated.  
Cases: preterm 
Controls: term (not defined) 
Sample size: n=27 
 
DNA 
Methylation 
(DLL1 and 
NOTCH 1) 
 
Ascertained: 
Sensitive 
Methylation-
Specific PCR 
Preterm birth 
(no GA cutoff; 
GA=24-32 
weeks vs. GA 
37-40) 
 
Ascertained: 
Not specified 
No test 
reported 
DLL1 methylation was 13% in cases vs. 0% in 
controls. 
None of the samples showed NOTCH 1 
methylation. 
Design: Eligibility criteria ill-
defined.  Blinding and non-response 
rate unknown. Recruitment methods 
and data management not described 
Analysis: No power analysis, no 
statistical test 
NOS : S=0, C=0, E=2 (Total=2) 
 
Sundrani et al., 
2014 
[25] 
Hospital 
based case-
control study 
Place/year: Pune, India, Year 
unknown  
Eligibility: Newborns from 
women with no medical 
diseases or obstetric 
complications (e.g., diabetes, 
preeclampsia, anemia, malaria, 
or infections such as HIV or 
hepatitis B surface antigen)  
Cases: preterm delivery 
Controls: term delivery 
Sample size: Variable (n=94-
109) 
DNA 
methylation/ 
mRNA 
(VEGF, FLT-I 
and KDR) 
 
Ascertained: 
Sequenom 
massARRAY 
EpiTYPER and 
RT-qPCR 
Preterm birth 
(GA <37 
weeks vs. GA 
≥37 weeks) 
 
Ascertained: 
Not specified 
 
t-test and 
correlation 
In the preterm group mRNA expression levels 
were lower for VEGF (p<0.05), higher for KDR 
(p<0.05) and similar for FLT-I vs. the term 
group.  
Overall, there was no difference in VEGF, KDR 
or FLT-I promoter methylation between the term 
and preterm groups. Individual CpG sites (3/23 
VEGF; 2/30 FLT-I and 1/37 KDR) were 
differentially methylated in the term vs. preterm 
groups (p<0.05). Methylation and mRNA 
expression of FLT-I were correlated in the 
preterm (p=0.031) but not the term group. There 
was no correlation in either group for VEGF or 
KDR.  
 
Design: Limited generalizability. 
Eligibility criteria unclear. Blinding 
and non-response rate unknown. 
Recruitment methods and data 
management not described. Unclear 
if batch effect.   
Analysis: No power analysis. 
Missing data not explained. 
Multiple comparisons. No 
adjustment for confounders. 
NOS : S=1, C=0, E=2 (Total=3) 
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Abbreviations: ACOG = American College of Obstetricians and Gynecologists, ANOVA = Analysis of variance, BDNF = Brain Derived Neurotrophic Factor, BS = Bisulfite 
Sequencing, DM = Differential Methylation, FLT-1: Fms-related Tyrosine kinase 1, GA: Gestational Age, HTN = Arterial Hypertension or High Blood Pressure, ISCU= Iron-
Sulfur Cluster Scaffold Homologue, KDR: Kinase Insert Domain Receptor, LMP=Last Menstrual Period, MMP=Metalloproteinase, MSP=Methylation-Specific PCR, NGF=Nerve 
Growth Factor, NOS: Newcastle Ottawa Scale, NT=Normal Term, OXTR=Oxytocin Receptor, PCR= Polymerase Chain Reaction, PE=Preeclampsia,  
PlGF: Placental Growth Factor, PPROM: Preterm Premature Rupture of Membranes, PROM: Premature Rupture of Membrane, PT= Preterm, PTB=Preterm Birth, PTL= Preterm 
Labor, PTPE= Preterm Pre-Eclampsia, RRR= Relative Risk Ratio, RT-PCR= Reverse Transcription Polymerase Chain Reaction, RT-qPCR= Real-Time Quantitative Reverse 
Transcription -Polymerase Chain Reaction, SGA: Small for Gestational Age, TL: Term Labor, TNL: Term No Labor, UCN=Urocortin, VEGF: Vascular Endothelial Growth 
Factor.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Summary of results for DNA methylation studies in preterm and term placentae. 
Author, Year Candidate 
Gene 
DNA Methylation in Preterm vs. Term Placentae p-valuea 
Hypomethylated Hypermethylated No Change 
Kim et al., 2013  
[21] 
OXTR  
UCN 
 X 
X 
 p<0.05 
Kulkarni et al., 2011  
[4] 
Global DNA  X  p<0.05 
Maccani et al., 2013  
[7] 
RUNX3  X  p<0.04 
Shimanuki et al., 2015  
[24] 
DLL1 
NOTCH1 
 X  
X 
n.r. 
Sundrani et al., 2014  
[25] 
VEGF  
KDR 
FLT1 
  X 
X 
X 
n.r. 
n.r. = not reported 
aThe p-value refers to all candidate genes within the same study unless otherwise stated 
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Table 3. Summary of results for miRNA and mRNA expression studies in preterm and term placentae. 
Author, Year  miRNA/mRNA Expression in Preterm vs. Term Placentae p-valuea 
  Downregulated Upregulated No Change  
miRNA 
Anton et al., 2015  
[18] 
miR-517a/b 
miR-517c 
 X 
X 
 p=0.0060 
p=0.0098 
Enquobahrie et al., 2015 
[20] 
miR-210  
miR-210 
miR-223 
X(A)  
 
 
  
X(C) 
X(C,A) 
p>0.05 
p<0.05 
p<0.05 
Lee et al., 2011 
[26] 
miR-210 X   n.r. 
Mayor-Lynn et al., 2011 
[22] 
miR-15b 
miR-181a 
miR-200c  
miR-210  
miR-483-5p  
miR-296  
miR-493 
  X 
X 
X 
X 
X 
X 
X 
All p>0.05 
 
Montenegro et al., 2009 
[23] 
miR-25  
miR-101  
miR-131a  
miR-142-3p  
miR-154  
miR-202  
miR-136 
miR-199a* 
miR-338  
miR-449  
 X (b) 
X (b) 
X (b) 
X (b) 
X (b) 
X (b) 
X(g,b) 
X(g,b) 
X(g,b) 
X(g,b) 
 n.r.(b) 
 
 
 
 
 
p<0.05(g) 
mRNA 
Dhobale et al., 2013 
[19] 
BDNF 
NGF 
X 
X 
  p<0.05 
p<0.05 
Enquobahrie et al., 2015 
[20] 
MMP2 
MMP9 
TIMP1 
n.r. 
 
n.r 
n.r. 
 
n.r. 
n.r 
X(C,A) 
n.r 
n.r. 
p>0.05 
n.r 
Kim et al., 2013 
[21] 
OXTR 
UCN 
 X (amnion) 
X (amnion) 
 p<0.05 
Mayor-Lynn et al., 2011 
[22] 
SOCS1  
ADAM17  
TIMP3  
CRH  
CRHBP ADAM30  
MMP1  
MMP9  
STC2 
  X 
X 
X 
X 
X 
X 
X 
X 
n.r. 
Sundrani et al., 2014 
[25] 
VEGF 
FLT1 
KDR 
X  
 
X 
 
X 
p<0.05 
 
p<0.05 
aThe p-value refers to all candidate genes within the same study unless otherwise stated 
(b) p-value for array analyses was not reported 
(g) p-value for RT-qPCR analyses 
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Supplemental Table 1. PUBMED search strategy. 
Search: ((placenta) AND (((((epigenetic) OR dna methylation) OR microRNA) OR histone) OR acetylation)) AND 
(((preterm labor) OR pprom) OR preterm birth) 
Mapped search: (("placenta"[MeSH Terms] OR "placenta"[All Fields]) AND ((((("epigenomics"[MeSH Terms] 
OR "epigenomics"[All Fields] OR "epigenetic"[All Fields]) OR ("dna methylation"[MeSH Terms] OR ("dna"[All 
Fields] AND "methylation"[All Fields]) OR "dna methylation"[All Fields])) OR ("micrornas"[MeSH Terms] OR 
"micrornas"[All Fields] OR "microrna"[All Fields])) OR ("histones"[MeSH Terms] OR "histones"[All Fields] OR 
"histone"[All Fields])) OR ("acetylation"[MeSH Terms] OR "acetylation"[All Fields]))) AND ((("obstetric labor, 
premature"[MeSH Terms] OR ("obstetric"[All Fields] AND "labor"[All Fields] AND "premature"[All Fields]) OR 
"premature obstetric labor"[All Fields] OR ("preterm"[All Fields] AND "labor"[All Fields]) OR "preterm labor"[All 
Fields]) OR pprom[All Fields]) OR ("premature birth"[MeSH Terms] OR ("premature"[All Fields] AND "birth"[All 
Fields]) OR "premature birth"[All Fields] OR ("preterm"[All Fields] AND "birth"[All Fields]) OR "preterm 
birth"[All Fields])) 
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Supplemental Table 2. EMBASE search strategy. 
Search: 'placenta'/exp OR placenta AND (epigenetic OR 'dna'/exp OR dna AND ('methylation'/exp OR 
methylation) OR 'microrna'/exp OR microrna OR 'histone'/exp OR histone OR 'acetylation'/exp OR acetylation) 
AND (preterm AND ('labor'/exp OR labor) OR pprom OR preterm) AND ('birth'/exp OR birth) 
Mapped search: 'placenta'/exp OR 'placenta' OR 'placenta'/exp OR placenta AND (epigenetic OR 'dna'/exp OR 
'dna' OR 'dna'/exp OR dna AND ('methylation'/exp OR 'methylation' OR 'methylation'/exp OR methylation) OR 
'microrna'/exp OR 'microrna' OR 'microrna'/exp OR microrna OR 'histone'/exp OR 'histone' OR 'histone'/exp OR 
histone OR 'acetylation'/exp OR 'acetylation' OR 'acetylation'/exp OR acetylation) AND (preterm AND ('labor'/exp 
OR 'labor' OR 'labor'/exp OR labor) OR pprom OR preterm) AND ('birth'/exp OR 'birth' OR 'birth'/exp OR birth) 
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CHAPTER 3 
DETERMINANTS OF PRETERM BIRTH IN A HAWAIIAN POPULATION:  
A CASE-CONTROL STUDY  
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Abstract 
 
Objective: Premature birth is a complex multifactorial process.  This study aims to assess 
predictor risks for singleton preterm births in a Hawaiian population. 
Methods: Using de-identified data collected by the University of Hawaii biorepository between 
2007 and 2013, we performed univariate and multivariate logistic regressions to assess potential 
predictor risks for preterm birth. 
Results:  Native Hawaiian and Pacific Islanders were significantly less likely to have a PTB.  
Lower maternal height (OR, 0.98; 95% CI, 0.97-0.99), chronic hypertension (OR, 1.87; 1.41-
2.48), eclampsia (OR, 1.87; 95% CI, 3.73-5.85), history of renal disease (OR, 2.26; 95% CI, 1.13-
4.51), and male infant (OR, 1.17; 95% CI, 1.02-1.35) were positively associated with higher risks 
of preterm birth.  
Conclusion:  Preterm births are due to a complex interaction of multiple predictor risks, and the 
primary cause often remains unknown.  Preterm birth preventive strategy could be directed to 
minimize chronic disorders such as hypertension and renal disease effects on pregnancy.  A 
comprehensive medical screening with environmental exposure evaluation should be given to all 
pregnant woman with chronic illnesses.  More investigation is needed on the impacts of placental 
dysregulation and socio-environmental factors, as well as in both fields of genetics and 
epigenetics to identify biomarkers for preterm birth. 
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Introduction 
Preterm birth (PTB) is a birth before the thirty-seventh-gestational week. Blencowe et al. 
(2012) estimated PTB to be about 5–18% of all live births worldwide.  In the United States in 
2014, 9.6 % of births (about 1 in 10 babies) occurred prematurely (March of Dimes, 2015).  PTB 
is a significant contributor to long-term infant morbidities such as an increased risk of severely 
impaired neurodevelopment, respiratory difficulties, feeding and digestive problems, and 
mortality (Blencowe et al., 2012; CDC 2015; Johnson et al., 2009; Stephens & Vohr 2009).  
Further, studies have found metabolic abnormalities such as reduced insulin sensitivity, high 
blood pressure, diabetes mellitus, and cardiovascular risks in adults born prematurely (Keijzer-
Veen et al., 2010; Mathai et al., 2015).  The etiology of PTB is understood to be a complex, 
multifactorial process not limited to triggering factors such as hemorrhage, cervical dysfunction, 
idiopathic contractions, infection, malnutrition, multifetal pregnancy and spontaneous preterm 
rupture of the fetal membranes (Goldenberg et al., 2007).  
PTB rates in the United States are highest among women of less than 20 and more than 
35 years of age.  Non-Hispanic black mothers are typically at highest risk, followed by Native 
American or Alaskan Natives, Hispanics, non-Hispanic whites, and Asian or Pacific Islanders 
(Martin et al., 2013; US DHHS, 2014).  Other risk factors for PTB such as low socioeconomic 
status, life events, and behaviors have been reported to be associated with PTB (Premji et al., 
2015).  Establishing causal relationships between most of these risk factors and PTB have been 
challenging for many reasons.  Various PTBs occur in women with no known risk factors, many 
women with risk factors do not have PTBs and obstetrical complications resulting in PTB likely 
involve unknown cofactors to exert their effect, making the chain of causality complex and 
difficult to document.  For example, maternal smoking and environmental tobacco exposure lead 
to genetic or epigenetic alterations, which can precipitate preterm labor (Knight et al., 2016; 
Maccani et al., 2013; Miyake et al., 2013).  Also, the effect of acute and chronic stress can be 
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preserved epigenetically in the fetus and lead to premature labor (Han et al., 2014; Radtke et al., 
2011; Shah et al., 2010). 
Prenatal care often focuses on identifying and treating the complications, rather than 
preventing them due to the problem in diagnosing and treating underlying causes of PTB.  
Studying risk factors of PTB in a population of pregnant women can be helpful in the prevention 
and the reduction of the prevalence of premature labor. Although many investigators have studied 
various risk factors for preterm birth in United Sates (Beck et al., 2010), very few studies have 
focused on a Hawaiian population where the majority is non-White.  To the best of our 
knowledge, no studies to date have used Hawaii biorepository data to assess risk predictors of 
singleton PTB. Therefore, this study aims to evaluate demographic, obstetric and medical risk 
factors of preterm labor. Such epidemiological information will help to guide clinicians, public 
health professionals, basic scientists, and health policy makers to identify indicators for 
monitoring preterm delivery strategy and applying the necessary preventive measure to decrease 
preterm birth in Hawaii.  A collaborative approach targeting PTB risk factors is needed to 
improve the adequacy of antenatal care services. Further, a systematic review (Chapter 2) showed 
that epigenetic placental dysregulations play a significant role in PTB, but some of the included 
studies in the review did not take into account many of the risk predictors of PTB and did not 
follow STROBE (STrengthening the Reporting of OBservational Studies in Epidemiology) 
guidelines. STROBE is a checklist guiding report of observational studies (von Elm et al., 2008).  
Findings from the present study will help focus on robust epigenetic studies to understand the 
etiology of PTB and other adverse pregnancy outcomes and inform the design of interventions to 
improve women’s health across the lifespan. 
Materials & Methods 
Study Setting and Study Population 
This analysis used data collected as part of the Human Reproductive Biospecimen 
Repository sub-project of the University of Hawaii Biorepository (UHB).  The reason for 
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selecting Hawaii biorepository for this dissertation was the availability of biospecimen for future 
epigenetic studies.  The UHB is a non-commercial, NIH-sponsored clinical data and biological 
samples (placenta and cord blood) repository created to assist researchers in reducing health 
disparities by accessing participants’ demographic information, clinical data and genetic 
information.  The UHB worked exclusively with Kapi’olani Women and Children’s Medical 
Center in Honolulu, Hawaii to recruit post-partum women to donate their placenta, umbilical 
cord, and the excess cord and maternal blood collected routinely for care purposes.  No 
information on the total participants who visited the clinic, participation was voluntary, and 
women were free to choose not to participate.  The actual participation and response rates were 
not provided by the UHB to this Investigator.  With informed consent, an abstract of participants’ 
Electronic Medical Record (EMR) information was automatically downloaded and appended to 
their demographic characteristics and biospecimen samples.  During the process, women self-
reported their racial and ethnic ancestry for the prior three generations.  The UHB recruited 9,242 
women-child pairs between 2007 and 2013, approximately 7% of the Hawaiian total births during 
the same period (US DHHS, 2017).  More than 400 maternal and 80 infant variables were 
abstracted from their EMR.  The Western Institutional Review Board approved the Human 
Reproductive Biospecimen Repository sub-project of the UHB (WIRB Study Number 1107593).   
Selection for current study 
The present study data analysis involved 8,191 (89% of the total women recruited) 
women ages 18 years or older who had a singleton birth, who could read, speak and understand 
English, and who gave birth within 24 hours after admission at Kapi’olani Women Children’s 
Medical Center. Of those 8,191 women, 1,288 had delivered before 37 completed weeks of 
gestation (cases or preterm birth group) and 6,903 at 37 or more completed weeks of gestation 
(controls or term birth) (Appendix A).  After removing records missing data on any of the key 
variables (20%), the final sample of the study consisted of 1,016 women in the preterm group and 
5,503 women in the term group, representing 78.9% and 79.7% of the eligible women, 
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respectively.  The 15.6% of preterm births in the final sample was nearly identical to the 15.7% 
observed in all eligible women.  All data received for this study were de-identified, and the study 
was determined to be exempt by the University of Nebraska Medical Center - Institutional 
Review Board. 
Analysis 
After completing logic checks, data were initially analyzed to produce descriptive 
statistics of the study population.  Chi-square tests were used to assess the strength of associations 
between the independent and dependent variables.  To determine case and control groups, we 
categorized gestational ages as preterm (< 37 week) and term birth (≥37 weeks).  Previous studies 
have highlighted an association between younger and older maternal age and preterm birth 
(Blomberg et al., 2014; Ferré, 2016; Waldenström et al., 2016).  To capture these associations we 
changed continuous variable maternal age to categorical variable. In addition, studied have found 
racial disparities in preterm birth and entering race in the model as it is will not capture this 
inequality (Burris et al., 2011; Raglan et al., 2016).  Therefore, we introduced maternal age and 
race groups as dummy variables in the model to capture inequalities across groups.  We used 
univariable and multivariable logistic regression analyses to calculate odds ratios (OR) of PTB 
for all covariates. Gestational age group (< 37 weeks (preterm birth) vs. ≥ 37 weeks (term birth)) 
was the dependent variable. Independent variables were dummy variable for maternal age (less 
25, 25 to 29, 30 and older) and race (White, Asian, Native Hawaiian/Pacific Islander, Other) 
groups, continuous measures of height (in cm) and pregravid weight (in kg), and dichotomous 
measures of alcohol use, smoking, diabetes (mellitus or gestational), chronic hypertension, 
eclampsia, asthma, history of renal disease, and infant sex.  Covariates for the full multivariable 
logistic regression model included dummy variables for maternal age and race groups, which 
were forced to remain in the models in order to consistently control for their effects.  Significant 
predictors among the remaining independent variables were identified using backward variable 
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selection with a p-value for removal to be larger than α=0.05.  All analyses used two sided 
α=0.05 and SPSS v23.0 statistical analysis software. 
Results  
Table 1 displays the demographic, behavioral and clinical characteristics of the study 
population.  The mean maternal age was 28.3 years and ranged between 15 and 50 years.  The 
mean pregravid weight was 66.9 kg (147.5 lbs.), and the average maternal height was 160.4 cm 
(63.1 inches).  More than half (55%) of the participating women were Asian, and the next largest 
group was Native Hawaiian/Pacific Islanders (22.1%).  A total of 52% of newborns were male; 
the average infant birth weight was 3,164 grams, and 79% were delivered vaginally.  The preterm 
group was 15.6 % (n=1,016) of the final sample  a significantly higher preterm rate than the 
10.4% observed for all Hawaiian total births during the study period (USDHHS, 2017; chi-square 
p-value < 0.001). Study women had a mean maternal age of 28.9 (SD 6.3) years and ranged 
between 18-48 years. Maternal age 30 and older, height less than 62.9 inches, chronic 
hypertension, diabetes, asthma, renal disease, and eclampsia were more frequent among women 
with preterm births.  Also, preterm births were more common among male infants. Chi-square 
tests showed significant associations between preterm births and eight independent variables: 
maternal age (p = 0.015), maternal race (p = 0.001), maternal height (p < 0.001), chronic 
hypertension (p < 0.001), diabetes (p = 0.001), history of renal disease (p < 0.001), eclampsia (p 
< 0.001), and infant sex (p = 0.020) (Table 1). The chi-square tests did not show significant 
differences between preterm births and maternal pregravid weight (p = 0.377), smoking status (p 
= 0.453) and alcohol use (p = 0.537). 
Table 2 displays the logistic regression analysis results.  The univariate analysis showed 
significantly (p < 0.05) associations between PTB and maternal height, diabetes, chronic 
hypertension, eclampsia, renal disease, and male infant sex.  Maternal weight, alcohol drinking 
and smoking were not associated with PTB. Using age (25-29) group as the reference, logistic 
regression analysis showed that the other age groups were not significantly associated with PTB 
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in the univariate and multivariate models.  Compared to White mothers, only Native 
Hawaiian/Pacific Islander women had significantly lower odds of PTB (OR, 0.78; 95% CI, 0.62-
0.97); no other racial comparisons were significant. In addition, there were a significantly lower 
OR of PTB among mothers for every cm increase in height (OR, 0.98; 95% CI, 0.97-0.99), and 
higher odds of chronic hypertension (OR, 1.87; 1.41-2.48), eclampsia (OR, 1.87; 95% CI, 3.73-
5.85), history of renal disease (OR, 2.26; 95% CI, 1.13-4.51), and male infant (OR, 1.12; 95% CI, 
1.02-1.35).  Diabetes was associated positively with PTB in the univariate model, but not in the 
multivariate model.  
 Discussion  
This study of a Hawaiian population has shown an incidence of PTB of 15.6%, a 
significant negative association between preterm birth and Native Hawaiian/Pacific Islander race, 
and significant positive associations between lower maternal height, diabetes, chronic 
hypertensive disorders, eclampsia, renal diseases, male infant sex, and PTB.  However, the 
association with diabetes was no longer significant in fully controlled models.     
Native Hawaiian newborns accounted for 22% of the final sample and resulted in 18% of 
all preterm birth. In the study sample, 45% of participants were of short stature.  This study found 
that the risk of preterm birth increased as maternal height decreased.  From a biological 
standpoint, shorter women are more likely to have a smaller pelvis and obstructed labor (Derraik 
et al., 2015; Stulp et al., 2011).  
This study showed that while women with diabetes had higher odds of preterm delivery, 
this association weakened when adjusted for other covariates in the multivariable analysis. In this 
study, chronic hypertension was associated with preterm birth.  This finding is comparable to that 
found by Catov et al. (2010).  Steer, found an association between preterm birth and renal and 
hypertensive pathologies (Steer, 2005).  These findings indicate the importance of chronic disease 
screening during prenatal care to prevent early birth. 
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The risk of preterm delivery was higher for male infant in this analysis. In general, 
medical decisions do not affect the sex ratio, but sex affects pregnancy outcome according to 
some studies (Challis et al., 2013; Di Renzo et al., 2007; Zeitlin et al., 2002).  For example, 
Zeitlin and colleagues suggested that the proportion of male births decreases with increasing 
gestational age (Zeitlin 2004). Challis et al., (2013) found that the occurrence of preterm birth is 
higher in gestations carrying a male fetus.  To explain these findings, some investigators pointed 
out to the sex hormone or the immune response to subsequent pregnancies (Mortensen et al. 
2011; Nielsen et al., 2010).  
There are some limitations associated with this study.  This data came only from one 
United States (U.S.) State and women in Hawaii are not representative of the entire U.S. Thus, 
generalization of these findings should be done with caution.  Also, there was no information on 
the total participants who visited Kapi’olani Women and Children’s Medical Center in Honolulu, 
Hawaii between 2013 and 2017.  Further, this data analysis used a limited variable set. Although 
the study included many significant risk predictors for preterm delivery, others were not added 
such as socioeconomic factors.  Finally, many studies have shown concerns with the secondary 
data analysis, such as missing data, linkage with vital records and limited information for some 
variables (Ancker et al., 2011; Bibb et al., 2007; Blucher et al. 2014). 
Conclusions  
Overall, 16% of the sample of this study population had a singleton PTB, higher than 
12.6% rate for total Hawaiian population in 2013 (March of Dimes, 2015).  Similar to other 
studies, this analysis found that having short stature, hypertension, renal disease, eclampsia, and 
male fetus increase the risk of preterm delivery.  PTB preventive strategy should be directed to 
helping women optimize their health and lifestyles, and consider treating chronic disorders before 
and during pregnancy.  This study supports the importance of appropriate screening for chronic 
diseases and related obstetric disorders to prevent or to manage medically preterm birth, an area 
deserving of continued study.  These data validate the evidence from other studies, confirm the 
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complexity of PTB, and reinforce the need for more investigations in the area of fetal 
development, socio-environmental factors, genetic and epigenetic factors.  When we refer to 
epigenetic (gene – environment interactions), these maternal and clinical factors represent the 
environmental insults causing direct and indirect placental epigenetic dysregulations.  The results 
of this study provide useful information (e.g. measurement and analysis of potential confounders) 
to design an unbiased placenta epigenetic modification study to understand adverse pregnancy 
outcomes including PTB mechanisms and inform recommendations to prevent and treat this 
multifactorial disease.  
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 Table 1 Proportion of maternal and infant characteristics among preterm and term birth groups (n=6519) 
 Preterm birth 
n =1016  
 Term birth  
n = 5503 
All participants 
n=6519 
χ2 P-value 
 n (%) n (%) n (%)   
Variables      
Maternal age (years)    8.42 0.015 
Less than 25 284 (28.0) 1762 (32.0) 2046 (31.4)   
25 to 29 270 (26.6) 1478 (26.9) 1748 (26.8)   
30 and older 462 (45.5) 2263 (41.1) 2725 (41.8)   
                                                   Mean age 28.90 28.21 28.32   
Maternal race    15.48 0.001 
Asian  619 (60.9) 3015 (54.8) 3634 (55.7)   
Native Hawaiian/Pacific Islander 183 (18.0) 1256 (22.8) 1439 (22.1)   
White/Caucasian 182 (17.9) 1051 (19.1) 1233 (18.9)   
Other (NA/AN, AA) 32 (3.1) 181 (3.3) 213 (3.3)   
Maternal BMI    2.75 0.432 
Less than 18.5 48 (4.7) 316 (5.7) 364 (5.6)   
18.5 - < 24.9 489 (48.1) 2710 (49.2) 3199 (49.1)   
25 - < 29.9 244 (24.0) 1279 (23.2) 1523 (23.4)   
30 and older 235 (23.1) 1198 (21.8) 1433 (22.0)   
Mean BMI 26.27 25.79 25.86   
Maternal height     13.14 < 0.001 
< 160 cm 506 (49.8) 2402 (43.6) 2908 (44.6)   
≥160 cm 510 (50.2) 3101 (56.4) 3611(55.4)   
                                              Mean height 159.30 160.57 160.37   
Maternal pregravid weight    0.12 0.377 
< 66 kg 608 (59.8) 3325 (60.4) 3933 (60.3)   
≥ 66 kg 408 (40.2) 2178 (39.6) 2586 (39.7)   
                                             Mean weight 67.00 66.83 66.86   
Maternal smoking    0.56 0.453 
Yes 159 (15.6) 811(14.7) 970 (14.9)   
No  857 (84.4) 4692 (85.3) 5549 (85.1)   
Maternal alcohol use    0.38 0.537 
Yes 32 (3.1) 154 (2.8) 186 (2.9)   
No 984 (96.9) 5349 (97.2) 6333 (97.1)   
Chronic hypertension    90.07 < 0.001 
Yes 103 (10.1) 189 (3.4) 292 (4.5)   
No 913 (89.9) 5314 (96.6) 6227 (95.5)   
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 Preterm birth 
n =1016  
 Term birth  
n = 5503 
All participants 
n=6519 
χ2 P-value 
Diabetes     11.40 0.001 
Yes 146 (14.4) 590 (10.7) 736 (11.3)   
No 870 (85.6) 4913 (89.3) 5783 (88.7)   
History of asthma    3.55 0.059 
Yes 171 (16.8) 800 (14.5) 971 (14.9)   
No 845 (83.2) 4703 (85.5) 5548 (85.1)   
History of renal disease    16.28 < 0.001 
Yes 16 (1.6) 26 (0.5) 42 (0.6)   
No 1000 (98.4) 5477 (99.5) 6477 (99.4)   
Eclampsia    282.85 < 0.001 
Yes 177 (17.4) 211 (3.8) 388 (6.0)   
No 839 (82.6) 5292 (96.2) 6131 (94.0)   
Infant sex    5.41 0.020 
Female 455 (44.8) 2683 (48.8) 3138 (48.1)   
Male 561 (55.2) 2820 (51.2) 3381 (51.9)   
 
  AA= African American NA=Native American AN=Alaska Native 
BMI=Body Mass Index  
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Table 2 Logistic regression analysis of risk predictors for preterm birth (n=6519) 
 Crude  Full Model  Final Model  
Variables B (SE) P-value ORc (95%CI) B (SE) P-value ORa (95%CI) B(SE) P-value ORa (95%CI) 
Maternal age  
(years) 
         
     Age    25 – 29   Reference Reference Reference 
     Under 25 -0.13 (0.09) 0.174 0.88 (0.74, 1.06) -0.12 (0.10) 0.196 0.88 (0.73, 1.07) -0.13 (0.10) 0.179 0.88 (0.73, 1.06) 
     30 and older 0.11 (0.08) 0.184 1.12 (0.95, 1.32) -0.003 (0.09) 0.969 1.00 (0.84, 1.18) -0.002 (0.09) 0.986 1.00 (0.84, 1.18) 
Maternal race           
     White Reference Reference Reference 
     Asian 0.17 (0.09) 0.063 1.19 (0.99, 1.42) 0.02 (0.10) 0.828 1.02 (0.84, 1.24) 0.02 (0.10) 0.870 1.02 (0.84, 1.23) 
     Native Hawaiian/    
Pacific Islander 
-0.17 (0.11) 0.125 0.84 (0.68, 1.05) -0.26 (0.12) 0.027 0.77 (0.61, 0.97) -0.26 (0.12) 0.029 0.78 (0.62, 0.97) 
    Other 0.02 (0.21) 0.921 1.02 (0.68, 1.53) -0.13 (0.22) 0.561 0.88 (0.58, 1.35) -0.11 (0.22) 0.616 0.90 (0.59, 1.37) 
Maternal height 
(cm) 
-0.03 (0.01) 0.000 0.98 (0.97, 0.98) -0.03 (0.01) 0.000 0.98 (0.96, 0.99) -0.03 (0.01) 0.000 0.98 (0.97, 0.99) 
Maternal pregravid 
weight (kg) 
0.000 (0.002) 0.801 1.00 (0.99, 1.00) 0.001 (0.002) 0.718 1.00 (0.99, 1.01) -- - -- 
History of alcohol 
use 
0.12 (0.20) 0.537 1.13 (0.77, 1.66) 0.05 (0.21) 0.796 1.06 (0.70, 1.59) -- - -- 
History of smoking 0.07 (0.09) 0.453 1.07 (0.89, 1.29) 0.09 (0.10) 0.401 1.09 (0.89, 1.33) -- - -- 
Diabetes  0.33 (0.10) 0.001 1.40 (1.15, 1.70) 0.13 (0.11) 0.246 1.13 (0.92, 1.40) -- - -- 
Chronic 
hypertension 
1.15 (0.13) 0.000 3.17 (2.47, 4.07) 0.59 (0.15) 0.000 1.81 (1.36, 2.41) 0.63 (0.14) 0.000 1.87 (1.41, 2.48) 
Eclampsia 1.67 (0.11) 0.000 5.29 (4.28, 6.55) 1.52 (0.12) 0.000 4.59 (3.65, 5.76) 1.54 (0.12) 0.000 4.67 (3.73, 5.85) 
History of asthma 0.17 (0.09) 0.060 1.19 (0.99, 1.43) 0.10 (0.10) 0.320 1.10 (0.91, 1.33) -- - -- 
History of renal 
disease 
1.22 (0.32) 0.000 3.37 (1.80, 6.31) 0.82 (0.35) 0.020 2.27 (1.14, 4.53) 0.81 (0.35) 0.021 2.26 (1.13, 4.51) 
Infant sex 
(ref=male) 
0.16 (0.07) 0.020 1.17 (1.03, 1.34) 0.16 (0.07) 0.027 1.17 (1.02, 1.34) 0.16 (0.07) 0.025 1.17 (1.02, 1.35) 
  
OR = Odd Ratios (ORc: Crude OR; ORa: OR adjusted for all other variables in the model)  
Other = African American, Native American /Alaska Native 
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Appendix  
 
Appendix A. Comparison of maternal and newborn variables between preterm and term birth  
 All participants  
(n=8191) 
Preterm Birth 
GA <37 weeks  
(n=1288) 
Term Birth 
GA ≥37 weeks  
(n=6903) 
 
Variable Frequency Percent Frequency % Frequency % P-Value  
Maternal age (years)       0.022† 
Less than 20 591 7.2 96 7.5 495 7.2  
20 to 24 2014 24.6 282 21.9 1732 25.1  
25 to 29 2185  26.7 337 26.2 1848 26.8  
30 to 34 1903 23.2 297 23.1 1606 23.3  
35 to 40 1151 14.1 210 16.3 941 13.6  
40 + 347 4.2 66 5.1 281 4.1  
Mean age  28.25       
Maternal race       0.017† 
Asian  4512 55.1 765 59.4 3747 54.3  
American Indian/Alaska Native  71 0.9 11 0.9 60 0.9  
Black  or African American 93 1.1 10 0.8 83 1.2  
Native Hawaiian/Other Pacific Islander 1879 22.9 260 20.2 1619 23.5  
White/Caucasian 1547 18.9 226 17.5 1321 19.1  
Other/More than one race 89 1.1 16 1.2 73 1.1  
        
Maternal BMI       0.136 
Less than 18.5 409 5.0 52 4.0 357 5.2  
18.5 - < 25 3632 44.3 556 43.2 3076 44.6  
25 - < 30 1701 20.8 265 20.6 1436 20.8  
30 - < 35 888 10.8 141 10.9 747 10.8  
35 - < 40 384 4.7 71 5.5 313 4.5  
40+ 277 3.4 40 3.1 237 3.4  
Unknown/Missing 900 11.0 163 12.7 737 10.7  
Mean BMI 25.9       
Maternal height       0.000 
Less than 160 cm 3498 42.7 607 47.1 2891 41.9  
160 cm and up 4427 54.0 632 49.1 3795 55.0  
Unknown/Missing 266 3.2 49 3.8 217 3.1  
 Mean height (cm) 160.4       
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Maternal pregravid weight       0.073 
<66 kg 4461 54.5 690 53.6 3771 54.6  
≥ 66 kg 2972 36.3 457 35.5 2515 36.4  
Unknown/Missing 758 9.3 141 10.9 617 8.9  
Mean weight (kg) 66.84       
Maternal smoking       0.052 
Yes 1216 14.8 214 16.6 1002 14.5  
No  6974 85.1 1074 83.4 5900 85.5  
Unknown/Missing 1 0.1 0 0 1 0.0  
Maternal alcohol use       0.172 
Yes 215 2.6 41 3.2 174 2.5  
No 7976 97.4 1247 96.8 6729 97.5  
Chronic hypertension       0.000† 
Yes 353 4.3 128 9.9 225 3.3  
No 7837 95.7 1160 90.1 6677 96.7  
Unknown/Missing 1 0.0 0 0.0 1 0.0  
Diabetes mellitus       0.156 
Yes 291 3.6 55 4.3 236 3.4  
No 7272 88.8 1149 89.2 6123 88.7  
Unknown/Missing 628 7.7 84 6.5 544 7.9  
Gestational diabetes       0.000† 
Yes 880 10.7 175 13.6 705 10.2  
No 7308 89.2 1112 86.3 6196 89.8  
Unknown/Missing 3 0.0 1 0.1 2 0.0  
History of asthma       0.048 
Yes 1151 14.1 205 15.9 946 13.7  
No 6623 80.9 1027 79.7 5596 81.1  
Unknown/Missing 417 5.1 56 4.3 361 5.2  
History of renal disease       0.001 
Yes 48 0.6 16 1.2 32 0.5  
No 8140 99.4 1272 98.8 6868 99.5  
Unknown/Missing 3 0.00 0 0.0 3 0.0  
Mid preeclampsia       0.125 
Yes 227 2.8 44 3.4 183 2.7  
No 7963 97.2 1244 96.6 6719 97.3  
Unknown/Missing  
 
1 0.0   1 0.0  
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Severe preeclampsia       0.000† 
Yes 229 2.8 159 12.3 70 1.0  
No 7961 97.2 1129 87.7 6832 99.0  
Unknown/Missing  1 0.0 0 0.0 1 0.0  
Eclampsia       0.003† 
Yes 7 0.1 4 .3 3 0.0  
No 8183 99.9 1284 99.7 6899 99.9  
Unknown/Missing  1 0.0 0 0.0 1 0.0  
Group B Streptococcus (GBS)       0.989† 
Positive 1956 23.9 225 17.5 1731 25.1  
Negative 4177 51.0 480 37.3 3697 53.6  
Unknown/Missing 2058 25.1 583 45.2 1475 21.4  
History of chlamydia       0.777 
Positive 573 7.0 93 7.2 480 7.0  
Negative 6173 75.4 974 75.6 5199 75.3  
Unknown/Missing 1445 17.6 221 17.2 1224 17.7  
History of gonorrhea       0.973 
Positive 58 0.7 9 0.7 49 0.7  
Negative 6031 73.6 926 71.9 5105 74.0  
Unknown/Missing 2102 25.7 353 27.4 1744 25.3  
Bacterial vaginosis       0.589 
Yes 85 1.0 16 1.2 69 1.0  
No 342 4.2 56 4.3 286 4.1  
Unknown/Missing 7764 94.8 1216 94.4 6548 94.9  
Chorioamnionitis       0.640 
Yes 1041 12.7 171 13.3 870 12.6  
No 6597 80.5 1046 81.2 5551 80.4  
Missing 553 6.8 71 5.5 482 7.0  
Placenta previa       0.000† 
Yes  95 1.2 51 4.0 44 0.6  
No 7479 91.3 1158 89.9 6321 91.6  
Unknown/Missing 91 1.1 7988 6.1 538 7.8  
Intrauterine Growth Restriction (IGR)       0.000† 
Yes 250 3.1 95 7.4 155 2.3  
No 7940 96.9 1193 92.6 6745 97.7  
Missing 1 0.0 0 0.0 1 0.0  
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Delivery mode       0.000† 
Vaginal 5963 72.8 843 65.5 5120 74.2  
C-Section 2227 27.2 445 34.5 1782 25.8  
Infant Sex       0.114 
Female 3929 48.0 591 45.9 3338 48.4  
Male 4260 52.0 695 54.0 3565 51.6  
Missing 2 0.0 2 0.1 0 0.0  
Neonatal malformations       0.000† 
Yes 9 0.1 8 0.6 1 0.0  
No 8182 99.9 1280 99.4 6902 100  
Infant weight        0.000† 
ELBW (<999g) 74 0.9 72 5.6 2 0.0  
VLBW (1000 - 1499) 96 1.2 96 7.5 0 0  
LBW (1500 – 2499)   720 8.8 530 41.1 190 2.8  
NBW (2500 – 3999)  6741 82.3 571 44.3 6170 89.4  
HBW (>4000) 551 6.7 12 0.9 539 7.8  
Unknown/Missing 9 0.1 7 0.5 2 0.0  
Mean 3169.24       
Placenta available       0.002† 
Yes 7486  91.4  1148 89.1 6338 91.8  
No 705 8.6 140 10.9 565 8.2  
 
 † Statistically Significant 
 GA – Gestational Age 
 P-values are based on sample size without missing data 
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CHAPTER 4  
SYNTHESIS AND FUTURE DIRECTIONS 
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The placenta plays a significant role in the proper growth and development of a fetus, but 
it still an under-investigated organ. Environmental factors influence the placental function, 
physiology and gene expression (Guo et al., 2008; Maccani et al., 2009). Thus, the interface 
between genes and environmental insults is more important during fetal intrauterine growth. This 
interaction known as fetal programming can inform the molecular character of fetal development 
(Baker et al., 1995; Maccani et al., 2009). Subsequently, there is an increasing interest in 
investigating the molecular character of these placental epigenetic modifications related to 
perinatal development.   
Preterm birth a multifactorial and complex condition. Treating and preventing PTB 
necessitate an understanding of environmental insults, genetic and epigenetic factors. The 
primary goals of this dissertation were to examine the current knowledge on associations 
between traditional risk factors and emerging epigenetic factors with PTB. This dissertation 
includes three chapters covering epigenetic and non-epigenetic factors shown to be risk 
predictors of PTB.   Chapter 1 reviewed our understanding of human placental physiology and 
function and then discusses known relationships with epigenetic changes and PTB. Chapter 2 
evaluated and graded available evidence from published, peer-reviewed epigenetic studies 
examining the association between human placental epigenetic modifications and PTB, and 
discussed methodological concerns. Finally, Chapter 3 explored risk predictors of PTB.  The 
relatively low strength of associations of predictor variables with PTB points to the complexity 
of the problem as well as the need of collaborative effort to address it.  Chapter 4 summarized 
and linked the review with research sections, and proposed future directions.  
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Synthesis 
 In Chapter 1, we discussed current knowledge in the field of human placenta 
development, dysregulation of placental epigenetics, and relationships to maternal or 
environment factors. Normal placental development relies on a complex and precise interplay of 
numerous physiologic processes and its severe dysfunction is clearly implicated in preterm labor.  
While multiple placenta-related disorders such as placenta previa are well characterized 
clinically, the origins of these conditions are poorly understood and classical genetics has been 
unable to provide comprehensive answers.    
Chapter 2 presents a considerable body of evidence that epigenetic modifications may 
play a key role in the development of such disorders.  First, DNA methylation appears to play 
significant roles in both normal and abnormal placental function and physiology (Bodnar et al. 
2015). Second, histone-modifying enzymes are heavily involved in the activation of genes that 
regulate the placental formation, and proper fusion of the trophoblast with the uterine lining 
(Chuang et al., 2006). Third, non-coding RNAs are involved in placental epigenetic 
modifications and can signal abnormal development (Fu et al., 2013; Wei et al., 2017).  In 
addition, Jansen and others found an association between epigenetic imprinting and placental 
pathologies (e.g., preeclampsia) and PTB (Jansen et al., 2015; McCullough et al., 2016).  
Lambertini and colleagues have also used imprinting patterns to identify biomarkers associated 
with environmental insults (Lambertini et al., 2008).  All of these findings support the premise 
that epigenetic changes are major contributors to both normal and abnormal placental function 
and thus the etiology of premature rupture of membranes or labor.  However, while promising, 
results from epigenetic studies are often contradictory and non-specific; much of the lack of 
clarity is likely the result of improper experimental design and insufficient quantities of patient 
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and genomic parameters measured.  Of the candidate genes and pathways covered in this 
systematic review, the genes UCN, OXTR, RUNX3, VEGF, KDR, DLL1, NOTCH, and miRNA 
(miR-210, -136, -199a, -338, -449) were the most promising candidates for further study. 
Chapter 3 provides the results of a classical epidemiologic study examining risk 
predictors of PTB in a Hawaiian population.  Results were similar to existing literature, 
identifying factors such as lower maternal height, maternal morbidities, and fetal male sex as 
predictors of PTB.  A significant feature of this study, however, was that it was centered on a 
Hawaiian population with a distinctive racial mixture.  The lower risk of PTB found for Native 
Hawaiian and Pacific Islander would typically imply racially associated genetic determinants of 
PTB.  However, the study population also hints at multi-generational, racially associated 
epigenetic determinants of PTB, including fetal imprinting 
Findings from these three chapters present compelling evidence that no one answer has 
been found to be associated with the etiology of PTB, and thus no single intervention, whether 
clinical or population-based, will have a sizeable impact on prevention.  A comprehensive 
approach is needed to determine how a diverse environment and genetic insults interact with 
normal and abnormal epigenetic processes in the placenta to direct the outcome of fetal 
development and pregnancy. 
Future Directions 
The findings from this dissertation point to a clear direction for future research, 
particularly for a rigorous examination of epigenetic modifications of specific placental genes 
involved in premature labor.  However, preliminary research is necessary to more rigorously 
identify candidate genes with physiological, pathological and clinical functions related to 
placenta and PTB.  Placental samples from the University of Hawaii Biorepository are well 
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suited to a case-control study examining the human genome variation (polymorphisms) in 
previously identified candidate genes. Combining clinical expertise, population-based research, 
and epigenetic science is a promising approach to reach a better understanding of the complex, 
underlying causes of PTB, and to inform recommendations for preventing and treating this 
multifactorial condition. 
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